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Abstract 
LIM domain binding protein 1 (Ldb1) is a chromatin looping factor that forms part of a 
transcriptional ‘pentameric complex’. Ldb1 contains two domains that are essential for 
looping: a self-association domain, and a LIM interaction domain (LID) that binds LIM 
proteins such as Lmo2, which in turn binds to DNA binding transcription factors, Tal1, E2a 
and Gata-1.  
It was proposed that the Gata-1 binding protein FOG1 could bind to the pentameric complex. 
GFP-tagged FOG1 was shown to bind the complex by multi angle laser light scattering, 
providing a mechanism by which the intrinsically weak Gata-1/FOG1 interaction is bolstered 
through binding to other units of the pentameric complex.  
Little is known about proteins that are distantly related to mammalian Ldb1. Two such proteins, 
Ldb1 from C. elegans and Adn1 from S. pombe were expressed in bacteria. They had generally 
poor solubility, but use of a maltose binding protein tag promoted solubility, and different 
expression systems may enable their further study.  
Ldb1 was reported to bind the E3 ubiquitin ligase protein, RLIM. No interaction could be 
detected between these proteins by yeast two-hybrid analysis using truncated or full length 
proteins. The interaction was detected in mammalian cells using FLAG pull-down 
experiments, but truncation mutants of these proteins could not be expressed. RLIM has high 
levels of predicted disorder, which may contribute to its degradation in both cell types. 
An assay was developed in which dimerization domains could stabilise disordered binding 
regions. Constructs containing GST, a coiled-coil domain of CtIP, or the leucine zipper of 
GCN4, were tethered to a test peptide and assayed for binding in yeast two-hybrid assays. The 
domains from CtIP and/or GCN4 allowed the interaction to be detected. Although the assay 
could not detect an interaction between RLIM and Ldb1, it shows promise for detecting 
interactions for disordered proteins, and can be adapted to different expression systems. 
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Chapter 1. Introduction 
 
Transcription plays a key role in development and disease processes. The switching ‘on’ and 
‘off’ of genes enables the tight control of cellular processes. This regulation is determined by 
sections of DNA that usually lie outside of the coding region. These regulatory elements may 
be separated by hundreds of kilobases such that their interactions with one another, or with 
transcriptional start sites must be induced [1]. The introduction of techniques such as 
chromosome conformation capture (3C) has expanded our understanding of how these 
regulatory DNA elements come into close proximity to regulate gene expression. One 
mechanism is the formation of chromatin loops, whereby distal chromosome elements, such as 
promoters and enhancers, are brought into close proximity [2, 3]. The promoter is a region of 
DNA, positioned close to the transcription start site, which must be bound by transcription 
factors to activate gene transcription. An enhancer (or distal promoter) behaves in a similar 
way, but is distant—often hundreds of kilobases away—from the transcriptional start site. 
Interactions between these regulatory elements enhance expression of their target genes.  
Transcription factors often form multiprotein complexes that can either up or down regulate 
gene expression [4]. Such complexes often aid in targeting specific genes and can participate 
in chromatin looping. For example, protein complexes can interact with one another as well as 
with DNA, thereby providing a physical mechanism by which enhancer and promoters are 
brought together (Figure 1.1).  
 
Figure 1.1 Schematic of enhancer-promoter mediated looping. Enhancer (E) is located hundreds of 
kilobases away from the promoter (P) of the gene. A sequence specific transcription factor (TF) or TF 
complex binds DNA sequences at the enhancer and promoter, bringing them into close proximity. 
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1.1 Chromatin Looping 
Many studies have confirmed the wide spread occurrence of long range DNA interactions 
involving enhancers and promoters that are required for gene regulation [5, 6]. One of the best 
studied examples of chromatin looping in mammals is the β-globin locus, which encodes a 
series of β-globin genes that are switched on and off at different stages of development. The β-
globin locus control region (LCR) contains a series of distal enhancers for the β-globin genes 
that are positioned far upstream from these genes [7-9]. Chromatin looping was confirmed in 
this system by 3C experiments [10, 11]. 
Chromatin looping can occur via several different mechanisms including Polycomb mediated 
looping, 5’–3’ gene looping and insulator mediated loops [12]. Polycomb mediated looping 
involves the formation of a loop between DNA regions bound by Polycomb-group proteins and 
promoters to cause transcriptional silencing. 5’–3’ gene looping occurs via a strong interaction 
between the promoter and terminator, which aids transcriptional memory. Insulator mediated 
loops effectively isolate gene coding segments of chromatin to ensure that enhancers target 
their appropriate promoter. Chromatin looping at the β-globin locus involves enhancer-
promoter interactions. This type of looping is thought to drive the majority of the functional 
output of the genome [12]. 
 
1.1.1 Ldb1 is a looping factor at the β-globin locus 
LIM domain binding protein 1 (Ldb1) has been identified as an important mediator of looping 
at the β-globin locus. Early studies in Drosophila melanogaster indicated that the Drosophila 
Ldb1 homologue, Chip, mediates long range DNA interactions. Genetic screens designed to 
identify proteins that reduced the activity of enhancers in wing segmentation in Drosophila 
identified CHIP as a candidate [13]. Chip mRNA was found in many cell types at all stages of 
development, including at many sites along salivary gland polytene chromosomes, which are 
markers of segmentation [14]. Embryos that lack CHIP lack segments and show reduced gene 
activation of many developmental genes. CHIP was shown to bind the LIM-HD (LIM-
homeodomain) protein, Apterous (Ap), but bound at many other sites that were not occupied 
by Ap, suggesting that CHIP could cooperate with other LIM-containing protein complexes to 
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facilitate promoter-enhancer interactions associated with segmentation and other 
developmental processes. 
In vertebrates, the involvement of Ldb1 in looping has focussed on the β-globin locus. The red 
blood cell master transcription factor Gata-1 (see sections 1.2.2 and 1.2.4) is essential for the 
up-or down regulation of many genes that are associated with the development of red blood 
cells [15, 16]. It was later found that many of these activated genes are bound by Ldb1-
containing complexes, and Ldb1 is essential for their expression. For example, chromatin 
immunoprecipitation assays were used to show that Ldb1-containing complexes bind β-globin 
enhancers within the LCR in vivo  [17]. The same study also reported the localisation of Ldb1 
(and associated complexes) to the β-globin promoter and LCR after induction of differentiation 
in MEL (murine erythroleukemia) cells using DMSO (dimethyl sulfoxide). The recruitment of 
these proteins suggests the occurrence of a long-range interaction between the LCR and the β-
globin gene [17]. Enhancers that had been previously identified as erythroid enhancers were 
examined for binding by Ldb1 and/or members of the complex using the UCSC genome 
browser, which allows the interactive visualisation of genome data. Binding by Ldb1-
containing complexes was found at these enhancers, suggesting that Ldb1 plays a role in 
transcriptional activation of target genes [18].  
ChIP-seq data showed that binding sites of the Ldb1-containing complexes are located both at 
the promoter of the β-globin gene and at sites that are long distance from its target genes [19]. 
Chromosome Conformation Capture sequencing (3C-seq) was carried out for the β-globin 
gene, and found an interaction between the LCR and the promoter. These data suggested that 
Ldb1-containing complexes allow the formation of chromatin loops [19].  
 
1.1.2 Physical properties of Ldb1 
Ldb1 contains a self-association domain at the amino-terminus (Ldb1SA) [20-22], and a LIM-
binding domain (LID) near its carboxyl-terminus [20] (Figure 1.2). The self-association 
domain can form dimers or higher order oligomers in vitro [22] and is thought to be a driving 
force in forming long range chromatin interactions associated with Ldb1 [19, 23]. The ~30-
residue LID domain binds to the LIM domains of Lmo (LIM only) and LIM-HD proteins (See 
Section 1.2), thus allowing Ldb1 to indirectly contact DNA via protein:protein interactions 
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within larger transcriptional complexes, or DNA-binding proteins, respectively [24]. The 
ability of Ldb1 to self-associate and associate with DNA as part of transcriptional complexes 
provides a mechanism by which it can form chromatin loops [22, 25].   
 
Figure 1.2 Schematic of Ldb1 domains. Ldb1 contains a self-association domain (SA) and Ldb/CHIP 
conserved domain (LCCD) at the N terminal and a LIM Interacting Domain (LID) near the C terminus.  
 
1.1.3 Ldb1 induced chromatin looping 
Ldb1 has been used to engineer artificial looping factors. Tethering Ldb1SA to an artificial zinc 
finger construct targeted to the β-globin promoter was able to force the formation of an LCR-
β-globin chromatin loop in G1E cells, which lack Gata-1 [23] (Figure 1.3). β-globin 
transcription was activated over a thousand-fold compared to cells lacking the artificial looping 
factor. These observations suggest that Ldb1-induced chromatin looping is sufficient to 
promote chromatin looping and thereby activate transcription [23]. 3C assays indicated that the 
chromatin loops formed took the same form as natural chromatin loops formed by Gata-1, 
indicating that this artificial system could be used to control gene transcription [23].  
It has been observed that a reduction or individual knockout of Ldb1, Gata-1, FOG1 (Friend of 
Gata-1) and EKLF, reduces chromatin looping and β-globin activation [17, 26, 27]. Ldb1-
depleted MEL cells have been used to demonstrate that the fusion of Ldb1SA to Lmo2, without 
being bound to Gata-1, can activate β-globin gene activation and LCR-looping, suggesting that 
an interaction between Ldb1 and Lmo2 is an important part of gene activation and LCR-
looping associated with these proteins [28].  
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Figure 1.3 Schematic of forced chromatin looping in Gata-1 deficient erythroblasts. A. Gata-1 
deficient erythroblasts do not contain Gata-1, inhibiting the formation of the transcriptional complex at 
the β-globin promoter, while still forming at the LCR. This prevents chromatin looping and gene 
transcription. B. The tethering of Ldb1SA to an artificial zinc finger (ZF) restored chromatin looping at 
the β-globin locus, allowing for gene transcription. Figure adapted from [23]. 
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1.2 LIM domain proteins 
Ldb1 was originally named due to its identification in a mouse cDNA screen for proteins that 
bound LIM domain containing proteins, whereby a protein probe containing the LIM domains 
of Lhx1 was screened against a mouse cDNA library [24]. LIM domains are zinc fingers that 
mediate protein-protein interactions (see Section 1.2.3) [29]. LIM domain proteins are common 
in eukaryotes, and carry out various functions such as cytoskeletal organisation [30] and 
transcriptional regulation [31]. LIM domain proteins can be expressed in either the nucleus or 
the cytoplasm, and sometimes shuttle between the two [29]. They are also found, albeit much 
less commonly, in prokaryotes [32]. Ldb1 interacts with a family of LIM domain proteins that 
comprises the Lmo proteins (which contain little more than two closely spaced, or tandemly 
arrayed, LIM domains) [33], and the LIM-HD proteins (which contain the same tandem LIM 
domains, as well as DNA-binding homeodomain and intrinsically disordered C-terminal 
regions [34]). Mammals have four Lmo proteins (Lmo1–4) and 12 LIM-HD proteins (Isl1/2, 
Lhx1-6/8/9, Lmx1a/b).  
 
1.2.1 Lmo proteins 
Lmo/LIM-HD proteins and their binding partners play roles in regulating cell-lineage 
specification. They have overlapping expression patterns in the developing central nervous 
system, which has led to the hypothesis that these proteins form a transcriptional code for cell-
type specification termed the LIM code [35]. Although all family members have important 
biological roles, this thesis is more concerned with Lmo proteins. 
Lmo proteins have a high sequence similarity in their LIM domains. Lmo1 and 3 are 89% 
identical, while Lmo4 is the most divergent (Figure 1.4). Lmo1 and Lmo3 have overlapping 
expression patterns, such that null Lmo1/Lmo3 mutations are lethal, whereas single mutants 
display no discernible phenotype, suggesting a redundancy in their functions [36].  
Lmo1 and Lmo2 were first discovered as protein products from chromosomal translocations 
associated with T cell acute lymphoblastic leukaemia (T-ALL) [37, 38]. Lmo1 is linked to the 
human translocation t(11;14)(p15;q11) [39], and Lmo2 to t(11;14)(p13;q11) [40]. In both cases 
the promoter regions of T-cell receptor genes are linked to the LMO gene, leading to the 
expression of Lmo1 or Lmo2 in T-cells. These proteins are not normally expressed in mature 
 
Chapter 1. Introduction   7 
 
 
 
T-cells, and their overexpression leads to T-ALL with a long onset period [40, 41] . Other 
members of the Lmo family are also linked to cancer development, with the overexpression of 
Lmo4 in breast cancer being strongly associated with aggressive disease [42, 43]. Less is 
known about the oncogenic activity of Lmo3, but it is thought to be involved in the progression 
of human neuroblastoma [44].  
The best studied of this protein family is Lmo2. It assists in the formation of Ldb1-containing 
complexes that regulate gene transcription during blood cell development [45]. As detailed 
above, (Section 1.1.3) these Lmo2- and Ldb1-containing complexes have been shown to bind 
in vivo to the β-globin LCR [17]. 
Lmo2 is widely expressed in most human tissues, with the highest levels of Lmo2 mRNA being 
found in the spleen, foetal brain [44] and foetal liver [46]. Lmo2 knockout mutations in mice 
lead to death during primitive haematopoiesis (early blood cell development) [47]. It is also 
required for angiogenesis (blood vessel remodelling) in embryonic development and tumour 
growth [40, 48].  
 
Figure 1.4 Sequence alignment of Lmo family proteins. Sequences of human LIM domain 1 (LIM1) 
and LIM domain 2 (LIM2) were aligned using Clustal Omega. Green indicates conserved residues, and 
yellow conserved similar residues.  
 
1.2.2 The pentameric transcriptional complex 
One of the best characterised multi-protein transcriptional complexes is the so-called 
pentameric complex (Figure 1.5), an Lmo- and Ldb1-containing complex that is involved in 
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the regulation of red blood cell development and expression of the β-globin locus. In practice, 
this is a set of closely related complexes, as different family members for each of the individual 
protein components can be substituted for one another. The archetypal complex contains Lmo2, 
Ldb1, Gata-1, Tal1 and an E2a protein (E12 or E47) [45]. Lmo1 can be substituted for Lmo2, 
Gata-2 for Gata-1 and Tal2, Lyl1 or Lyl2 for Tal1. The pentameric complex was first proposed 
when all five archetypal proteins were found to be required to form a DNA-binding complex 
in MEL cells that would allow transcriptional transactivation of the β-globin promoter in 
luciferase assays [45]. EMSAs (Electrophoretic mobility shift assays) using MEL cell nuclear 
extract and different oligonucleotides were used to show that the pentameric complex binds a 
bipartite DNA motif that contains E-box (CANNTG) and GATA sites (WGATAR) [45]. As 
described above (Section 1.1.3), chromatin binding and gene expression studies have 
demonstrated that the pentameric complex is associated with Gata-1-activated genes [49], and 
3C studies demonstrated that Gata-1 and Ldb1 are required for looping at the β-globin locus 
[17, 27]. 
 
Figure 1.5 Schematic of the Lmo2 pentameric transcription factor complex. Tal1/E2a binds E-box 
sites on DNA (CANNTG) while Gata-1CF binds GATA DNA sites (WGATAR). Gata-1NF binds Lmo1 
or 2, which bridges the complex by also binding E2a/Tal1 and Ldb1LID. 
The basic helix loop helix (bHLH) proteins Tal1 and E2a proteins play roles in developmental 
processes in haematopoiesis and the nervous system [50, 51]. The E2a gene has two splice 
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variants which can be involved in this complex, E12 and E47, both of which are class I bHLH 
proteins [52].  
1.2.3  LIM domains and LIM-Ldb1 complexes 
The term LIM is derived from the three genes in which the motif was first observed, Lin-11 
Isl-1 and Mec-2 [53].  LIM domains are rich in cysteine and histidine residues, using these and 
some other residues to coordinate two zinc ions, thereby forming two zinc-binding modules in 
a sequential manner. Each zinc binding module contains a small hydrophobic core, with the 
zinc ions coordinated in a tetrahedral fashion [54]. LIM domains are structurally similar to 
Gata-type zinc fingers; each zinc-coordinating module in LIM domains assumes a Gata fold 
with two beta hairpins and an alpha helix. However, whereas Gata-type zinc fingers are best 
known for binding DNA, LIM domains do not. Instead they function by mediating protein-
protein interactions [54].  
LIM domains from Lmo proteins are often difficult to produce recombinantly as they tend to 
be insoluble and are prone to aggregation [55]. This issue can be overcome by engineering 
‘tethered complexes’, whereby the LIM domains are fused to the LID domain of Ldb1 (or other 
peptide LIM-binding domains) via a flexible glycine/serine linker that allows the domains to 
interact  [56, 57]. These fusion proteins tend to be soluble and stable. Structures of multiple 
LmoLIM-LID complexes have been determined using such tethered complexes [57-61].  
Ldb1LID binds the LIM domains of Lmo and LIM-HD proteins in an extended fashion forming 
a beta zipper structure [62] in which short beta strands in Ldb1LID extend the beta hairpins in 
the LIM domains to form small antiparallel beta sheets (shown for Lmo2-Ldb1LID in Figure 
1.6) [57]. These interactions are characterised by backbone-backbone hydrogen bonds and 
hydrophobic interactions, as well as a small number of electrostatic interactions that are likely 
to help define the register of binding [57, 63].  
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Figure 1.6 Structure of Ldb1LID bound to Lmo2. Ldb1 (red) bound to Lmo2 (green) with zinc atoms 
in grey. PBD:2XJZ [59].  
 
1.2.4 Gata-1 bound to DNA 
Gata proteins contain an N-terminal activation domain as well as an N-terminal zinc finger (N-
finger; Gata-1NF) and a C-terminal zinc finger (C-finger; Gata-1CF). Gata-1CF binds DNA at 
GATA sites with a high affinity and specificity [64]. Alone the N-finger can bind DNA weakly 
at GAT(C/G) sequences [65], however, it can assist DNA binding at double GATA sites [66, 
67] (Figure 1.7). It has also been shown to interact with FOG [68]. 
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Figure 1.7 Gata-1 zinc fingers bound to DNA. Gata-1 N-terminal finger (Gata-1NF) shown in yellow. 
Gata-1 C-terminal finger (Gata-1CF) shown in red. DNA shown in grey and zinc atoms shown as greys 
spheres. PDB: 4HCA [69]. 
 
1.2.5 Tal1/E47 binding to DNA 
Tal1 and E47 each contain a bHLH domain that can form heterodimers [70], which facilitate 
binding to E-box sites on DNA [52]. E2a proteins can homodimerize or heterodimerise with 
class II bHLH proteins such as Tal1. Class II bHLH proteins, such as Tal1, are required to 
dimerise with class I bHLH proteins to bind DNA [71] (Figure 1.8). Tal1 and E2a proteins can 
form homo- or heterodimers, but preferentially form heterodimers [71].  
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Figure 1.8 Tal1-E47 bound to DNA. Tal1 (red) and E47 (yellow) heterodimerise to bind DNA (grey). 
PDB: 2YPB [72].  
  
1.2.6 Assembly of the pentameric complex 
The binding of subsets of components of the pentameric complex to form subcomplexes has 
been investigated using a variety of biophysical and structural techniques. The binding of 
Lmo2-Ldb1LID to Tal1/E12 on DNA has been characterised using EMSAs, and isothermal 
titration calorimetry shows that Lmo2-Ldb1 binds the Tal1/E12 heterodimer ~300 fold more 
tightly than to Tal1 homodimers [73]. In contrast, Lmo2-Ldb1 cannot bind E12 in the absence 
of DNA [73]. MALLS/SEC (Multi-Angle Laser Light Scattering/Size Exclusion 
Chromatography) has shown that the Lmo2-Ldb1/Tal1/E12 complex forms with 1:1:1 
stoichiometry. The structure of Lmo2-Ldb1 bound to Tal1/E47 on DNA has been determined 
[72]. In this structure, the interaction is largely mediated by Lmo2LIM1, with only two residues 
of Lmo2LIM2 participating in the interaction. The LIM1 domain mainly binds the second helix 
and loop of Tal1, and makes only a few contacts with E47 [72]. One or two residues that lie 
between the LIM domains may act as a hinge, providing the two LIM domains with the ability 
to have some flexibility relative to each other in the presence of Ldb1LID [74].  
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NMR (nuclear magnetic resonance spectroscopy) chemical shift perturbation experiments 
demonstrated that Gata-1NF was sufficient for binding to Lmo2-Ldb1, with the interaction 
being mediated by the Gata-1NF and Lmo2LIM2 [75]. HADDOCK was then used to generate a 
model of the Gata-1NF/Lmo2LIM2-Ldb1LID complex based on chemical shifts. EMSA analysis 
confirmed that both LIM domains of Lmo2 were required for Tal1/E2a binding, and that the 
complex contacted DNA via Tal1/E2a heterodimers and Gata-1CF [75].  
Overall in this complex Gata-1 and an E2a/Tal1 heterodimer bind DNA via the WGATAR and 
E-box sites, respectively, and Lmo2 acts as a bridging protein [46], contacting each of those 
DNA-binding transcription factors [76], as well as Ldb1. 
 
1.2.7 Gata-1 and FOG proteins interact in the pentameric complex 
FOG1 is required for erythrocyte and megakaryocyte development and its deletion leads to 
embryonic cell death [15, 77]. FOG1 can act as either a co-repressor [78] or as a co-activator 
[79] through different mechanisms. For example, a short N-terminal domain of FOG1 can bind 
the NuRD (nucleosome remodelling and histone deacetylase) corepressor complex both in vivo 
and in vitro [80, 81]. NuRD possesses histone deacetylation activity that represses the 
transcriptional activation state of chromatin. Murine FOG1 contains nine zinc fingers, of which 
fingers 1, 5, 6 and 9 can independently interact with Gata-1 [78]. Although the Gata-1/FOG1 
interaction is very weak in vitro, Kd ~ 10
-5 M [68], Gata-1 activity appears to depend on the 
recruitment of FOG1 [79]. A mutation in Gata-1 (V205M), which causes the familial human 
blood disorders anaemia or thrombocytopenia, disrupts the interaction whereas secondary 
compensatory mutations in FOG1 that reinstate the interaction also restore biological activity 
[82]. Mutations in the N-terminal of FOG1 that disrupt interactions with the NuRD complex 
also impair Gata-1/FOG1-mediated transcriptional repression [80].  
The Gata-1NF can simultaneously bind FOG1 and Lmo2 through different surfaces on the 
protein [75, 82]. FOG1 and DNA can both bind the Gata-1NF at the same time [82], whereas 
Gata-1NF cannot contact both DNA and Lmo2 due to steric hindrance [75]. The Drosophila 
melanogaster homolog of FOG1 finger 1, U-shaped finger 1 (USF1) has 35% sequence identity 
with the mouse variant (Figure 1.9), and binds Gata-1NF in the same manner. Experiments using 
USF1 gave rise to better NMR spectra than the mouse variant and was thus used to determine 
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the structure of the Gata-1NF:USF1 complex using HADDOCK modelling based upon 
constraints derived from NMR spectroscopy [82]. 
 
 
 
Figure 1.9 Sequence alignment of mouse FOG finger 1 and U-shaped finger 1. Sequences of mouse 
FOG finger 1 (mFOG-F1) and the Drosophila melanogaster homolog, U-shaped finger 1 (USF1). 
Green shown conserved residues. Yellow shows similar residues. Bold indicates residues involved Zn 
binding [78].  
 
1.3 Ldb1 dimerisation 
One of the key properties of Ldb1 in terms of chromatin looping is its ability to self-associate 
via the Ldb1SA [28]. The structure of the Ldb1SA dimer has been determined in our laboratory 
(I. MacIndoe & A. Silva, unpublished data). This crystal structure contains an unusual cavity 
located at the dimer interface, which is of an appropriate size to accommodate molecules of 
approximately 600 Da (Figure 1.10). If this cavity is biologically relevant, small molecules that 
bind in the cavity could assist in the regulation of Ldb1 dimerisation, and thus chromatin 
looping and gene transcription. If such molecules could be found, it could a new means of 
transcriptional regulation through targeting the cavity.  
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Figure 1.10 Crystal structure of the Ldb1SA dimer. Structure of Ldb1SA dimer with subunits shown 
in yellow and orange. The proposed cavity is shown in grey (I. MacIndoe & A. Silva, unpublished data).  
 
1.3.1 Ldb1-like proteins 
Although Ldb1 has been extensively studied, less is known about proteins from other 
organisms that may act in a similar manner to mediate chromatin looping at other genomic loci. 
It would be of interest to investigate the properties of these proteins, and determine their 
commonalities and differences from Ldb1. It is reasonable that Ldb1-like proteins may self-
associate to mediate chromatin looping. This thesis involves some investigation of two such 
proteins, Ldb1 from Caenorhabditis elegans (CeLdb1) and Adn1 (Adhesion defective protein 
1), from Schizosaccharomyces pombe. These proteins were selected as they had varied degrees 
of sequence similarity to Ldb1SA. CeLdb1 appears to be closely related to mammalian Ldb1, 
while Adn1 is more distantly related.  
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CeLdb1 has been shown to specifically bind Lmo and LIM/HD proteins from C. elegans. For 
example, it binds the LIM-HD proteins CEH-14 and MEC-3 [83]. The same study showed that 
CeLdb1 is required for the function of several neurons, reflecting the roles of Ldb1 and LIM-
HD proteins in vertebrate neural development [83]. Ldb1 is expressed during vulval 
development, showing overlapping expression patterns with the LIM-HD protein Lin-11, 
allowing the possibility of an interaction in those cells [84]. CeLdb1 has not yet been shown to 
self-associate, however, the region thought to be responsible for self-association (residues 25–
231) shares 33% sequence identity with the human Ldb1 self-association domain.     
Adn1 may be a transcriptional regulator, involved in cell adhesion [85]. It shares sequence 
homology with SEUSS, a transcription factor involved in plant development in Arabidopsis 
Thaliana [86]. Adn1 also contains a region (residues 1–203) that shares 23% similarity with 
the self-association domain of human Ldb1. 
 
1.4 RLIM-Ldb1 interactions 
Ldb1 has various other known binding partners, some of which may regulate the lifetime of 
the pentameric complex. This includes the single stranded binding protein (SSBP), which 
stabilises Ldb1 and CHIP [14, 87], and Really Interesting New Gene (RING) finger LIM-
domain interacting protein (RLIM), which targets Ldb1 and binding partners of Ldb1, 
including other members of the pentameric complex, for degradation [88].  
RLIM [88] is encoded by the gene Rnf12 and is highly conserved across human, chicken and 
mouse [89]. RLIM is widely expressed during mouse embryogenesis. It localises mainly to the 
nucleus where it may exert an inhibitory or transcriptional activation effect on other 
transcription factors [90]. RLIM appears to exert its inhibitory effect via a histone deacetylase 
corepressor complex involving the protein Sin3A [88]. RLIM can be activated by several 
transcription factors, including those involved in the NOTCH signalling pathway, which like 
Lmo/LIM-HD proteins, are known to play a role in embryogenic development [89]. 
Overexpression of RLIM is linked to developmental abnormalities, via the disruption of limb 
growth, as its regulation is required for the proper formation of distal structures [88]. Previous 
studies have linked RLIM to pathogenic states such as breast cancer. RLIM and Ldb1 were 
found to interact with the oestrogen receptor ERα, and may regulate ERα expression during 
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breast cancer development [90]. RLIM expression may also be inhibited by the tumour 
suppressor protein p53, which has been found to decrease RLIM mRNA and protein levels by 
preventing its transcriptional activation [91]. 
RLIM is a RING H2 zinc finger protein.  This RING H2 domain enables RLIM to act as an E3 
ubiquitin protein ligase that can target Ldb1 and Ldb2 and protein partners (including Lmo2, 
Lmo4, Lhx2 and Lhx3) for degradation via the ubiqutin-proteosomal pathway [88]. 
Interactions between LIM domains and Ldb1 are necessary for RLIM-mediated ubiquitination 
and subsequent degradation, suggesting that RLIM specifically recognises Ldb1 and not the 
partners [92]. Thus, although initial co-immunoprecipitation and GST pull-down assays 
suggested an interaction between RLIM and the LIM domain of Lmo2 and Lhx3, these 
interactions are more likely to be indirect [88]. Direct RLIM-Ldb1 interactions were 
demonstrated in GST pull-down assays and in vitro ubiquitination assays in which Ldb1 was 
labelled with 35S and the ability of RLIM to ubiquitinate the protein was assessed [92]. As part 
of the same study, Ldb1 levels were monitored in a gonadotrope pituitary cell line αT3, where 
transfection of RLIM was found to decrease levels of Ldb1.  
RLIM contains several domains including a nuclear localisation domain, a RING domain and 
the so-called basic domain (RLIMBD; residues 326–403; Figure 1.11B), the latter of which was 
shown to bind Ldb1 in GST pulldown assays [92]. 
Whereas RLIM targets Ldb1-containing complexes for degradation, SSBP stabilises the same 
complexes [93]. The forced expression of SSBP inhibited RLIM-dependent Ldb1 and Lmo2 
degradation and increased Ldb1 expression, effectively stabilising the proteins [93]. SSBP2 
does not directly interact with Lmo proteins, but does contribute to complexes containing Lmo2 
and Ldb1. The presence of SSBP2 in immunoprecipitation assays decreased the affinity of 
RLIM for Ldb1 [93]. These findings suggested that the interaction between SSBP and Ldb1 
prevents RLIM from binding and ubiquitinating the protein [93]. RLIM and SSBP may thus 
compete for binding at the same site on Ldb1 to regulate protein levels. Experiments in the 
laboratory have confirmed that SSBP proteins bind to the Ldb1/CHIP conserved domain 
(LCCD; residues 214–223; P. Stokes, unpublished data). However, it has not yet been 
determined which portion of Ldb1 is involved in the interaction with RLIM. 
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Figure 1.11 Structural domains of Ldb1 and RLIM. A. Ldb1 contains a self-association domain 
(SA) and Ldb/CHIP conserved domain (LCCD) at the N terminal and a LIM Interacting Domain (LID) 
near the C terminus. B. RLIM contains a nuclear localisation domain (NLS), a basic domain (BD) and 
a RING (really interesting new gene) domain.  
 
1.5 Intrinsically disordered proteins 
The study of intrinsically disordered proteins (IDPs) and regions (IDRs) has greatly expanded 
over the last decade. IDPs and IDRs are defined as having no intrinsic defined structure. IDPs 
and IDRs are highly abundant in eukaryotes; up to 44% of human proteins are predicted to 
contain disordered segments of greater than 30 residues [94]. They are more abundant in 
eukaryotes than prokaryotes, which suggests an evolutionary role in supporting complexity 
[95]. Disordered segments may have arisen via the extension of existing exons in previously 
non-coding regions during evolution [94]. The predisposition of a protein towards disorder is 
encoded in its amino acid sequence. IDPs/IDRs are low in order promoting residues (Cys, Trp, 
Tyr, Phe, Ile, Leu, Val and Asn) and high in disorder-promoting residues (Pro, Arg, Gln, Gly, 
Ser, Glu, Lys, Ala) [96]. In more general terms, IDPs/IDRs are made up of simpler amino acid 
sequences, with less information volume [97] and a low hydrophobic content with a high net 
charge [95]. Their ordered, or folded state is unstable when free in solution [95].  
IDPs and IDRs are highly dynamic [98]. Despite their lack of structure, they are not completely 
flexible. They may adopt an extended conformation if their sequence has a high net charge and 
low hydrophobicity, or a compact formation if they have a balance between hydrophobicity 
and net charge [99]. The high net charge in extended IDPs and IDRs causes strong electrostatic 
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repulsion between similarly charged residues, and the lack of hydrophobic residues results in 
weak hydrophobic attractions [98].  
Proteins with disordered segments can have highly conserved regions of disorder. These 
conserved regions may have one or more varied functions but are most commonly involved in 
DNA, RNA and protein binding [94]. The length of a disordered region can give an indication 
of function. Generally, short IDRs act as linkers or contain molecular recognition features, 
while long IDRs can be entropic chains or contain motifs and domains that function in 
recognition. More specifically, IDRs of 300–500 residues are acted upon by modifying 
enzymes, such as kinases and phosphatases. Long IDRs (>500 residues), are found to be most 
commonly found in proteins with transcriptional related functions. Those with less than 50 
residues are generally found to mediate metal ion binding, ion channels and GTPase regulatory 
functions [94]. The function of IDPs have also been grouped based on the position of the 
disordered region. Disordered N-terminal regions are commonly associated with DNA binding 
proteins, while disordered C-terminal regions are linked with transcriptional repression or 
activation [94].  
 
1.5.1 Functions of IDPs  
The properties of IDPs provide several advantages in cell signalling pathways. Their lack of 
structure allows them to avoid steric hindrance in binding [95]. IDPs and IDRs generally bind 
with low affinity, often with rapid on-rates, which can be crucial for rapid responses in 
regulatory and signalling functions. An extended conformation can allow large binding 
interfaces, thereby conferring high specificity, which is important for signal recognition, 
transduction and regulation [95].  
The conformational flexibility of IDPs make them effective targets for post-translational 
modifications (PTMs). Flexibility exposes modification sites, making them accessible for 
binding by modifying enzymes. Proteome wide data searches of PTMs have found 
phosphorylation to occur with a higher frequency in regions of predicted disorder [100]. Other 
site-specific PTMs, such as O-glycosylation and ubiquitination have been found to occur 
primarily in disordered regions [101]. Ubiquitination and subsequent degradation can be 
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increased relative to folded regions of proteins, enabling protein levels in the cell to be rapidly 
controlled [95].  
The structure and folding of most small globular proteins is encoded by their amino acid 
sequence. For IDPs that fold upon binding, at least part of the information about folding is 
encoded by their binding partner, which allows some IDPs to adopt different folds with 
different binding partners [97].  
Other IDPs must remain unfolded to carry out their function. One such example is tau, involved 
in Alzheimer’s disease, which contains a disordered N-terminal domain that maintains an 
extended disordered conformation upon binding to tubulin, such that it can bind to several 
tubulin dimers [102]. This illustrates the importance of conformational flexibility. When IDPs 
remain disordered upon binding, they form a so-called ‘fuzzy’ or dynamic complex’ [97].     
 
1.5.2 Expression and purification of IDPs  
Disorder provides both advantages and disadvantages in the cell, and for expression and 
purification in the laboratory. IDPs are more resistant to high temperatures and pH, where they 
tend to remain soluble, while structured proteins will aggregate. This property may be used to 
purify IDPs [98]. However, the expression of IDPs is often hindered by aggregation during 
expression. This can at times be minimised by lower growth temperatures, growth in protease 
deficient bacteria, or fusion to carrier proteins that will promote the solubilisation of the target 
protein into solution (such as MBP or GST) [98].  
Disordered proteins, such as the Aβ40 peptide that is involved in Alzheimer’s disease, have 
been investigated for their ability to become more ordered at higher temperatures. For example, 
NMR-guided metadynamics, which probes structural features of proteins not available with 
other methods, can be used to give atomic level characterization of relevant conformational 
states [103]. Aβ40 was shown to be highly unstructured based on its free energy landscapes, 
but at higher free energies, partially structured conformations were formed, and the peptide 
became more compact. These experiments provided further evidence for the idea that IDPs 
become more ordered at higher temperatures.  
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IDPs have a low packing density, which can prevent aggregation. Thus, fusion of disordered 
proteins to ordered proteins may facilitate higher levels of soluble protein expression for the 
ordered protein. This property may be a mechanism by which some IDPs can act as chaperones 
[95]. Other IDPs are more susceptible to degradation, which can have a negative impact on 
expression and purification. STIL proteins, which are involved in mitosis, contain disordered 
domains that have been expressed with a lipoyl-domain tag. However, following removal of 
the tag these domains aggregated [104].  
One main disadvantage that arises when studying IDPs is their susceptibility to proteolysis. 
Their lack of structure results in exposed protease sites. Degradation during expression can be 
minimized using bacterial expression strains such as BL21(DE3) which lack the lon protease; 
however, this approach may not fully protect proteins from degradation [105]. Protein inhibitor 
cocktails and carrying out procedures at low temperatures were used to successfully express 
the disordered CECN1 N-terminal domain. In addition, mutation of cysteine residues to serine 
was found to decrease aggregation and improve long term storage [106]. Expression of the 
proteins in non-cytosolic compartments can also decrease protease digestion. Thus, methods to 
avoid proteolytic degradation include the use of periplasmic or extracellular secretion systems, 
thioredoxin fusion systems or production of target proteins in inclusion bodies. Chimeric 
membrane protein based methods for expression followed by purification with a C-terminal 
histidine tag can decrease the digestion of samples [105]. The expression of proteins in 
inclusion bodies often requires a re-folding step, but this is not an issue for IDPs because they 
do not need to be refolded. IDPs can be targeted to inclusion bodies using fusion proteins such 
as PagP as a C-terminal tag [107]. This approach facilitates expression, but the fusion partner 
must be removed for further analysis, usually under conditions that do not allow enzymatic 
proteolysis [107].      
Fusion to partner proteins may also circumvent IDP degradation by hiding protease sensitive 
sites. Alternatively, ‘nanny’ chaperones may be used [95], or the formation of a functional 
complex in vivo can prevent degradation [108]. The nanny model involves the use of a nanny 
protein which binds the IDP. Normally an IDP is susceptible to degradation, but when a nanny 
protein is present, the IDP may bind the nanny protein transiently before components of the 
functional complex bind the IDP, thus increasing its stability (Figure 1.12) [109].   
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Figure 1.12 Schematic of the ‘nanny’ model. Intrinsically disordered proteins are susceptible to 
degradation when synthesised. Nanny proteins can prevent this by binding the IDP, allowing this IDP 
to form a part of a functional complex. Adapted from [109]. 
An IDP and its partner protein may be co-expressed to prevent degradation. For example, a 
study investigating the nuclear hormone receptors mouse CBP and human ACTR, which are 
both intrinsically disordered in isolation, found that co-expression was essential for the 
successful expression and purification of both partners [110].  
 
1.5.3 Physical properties of IDPs 
The dynamic nature of IDPs makes them difficult to study by some methods, but NMR can be 
effective for probing their structure propensities and dynamics [111]. A protein that is 
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disordered in solution gives a highly or moderately dispersed 2D 1H-15N HSQC resonance 
pattern [105]. NMR also permits the detection of local disorder, folding upon binding, and 
disorder in a complex [94]. Small-angle X-ray scattering (SAXS) has been utilised to determine 
hydrodynamic parameters and degree of globularity of a protein, which can indicate if a protein 
is compact or unfolded [94]. Various single molecule methods are also used when studying 
disordered proteins. One small molecule method commonly used is single molecule FRET 
(smFRET). smFRET measures dynamics and individual conformations of the unbound 
ensemble, intermediates during folding and internal friction during the folding process. These 
measures can give information of the amount of disorder before and after binding [94].   
High throughput proteomic approaches have been used to identify a wide variety of IDPs. 
Cellular extracts can be enriched for disordered proteins, for example, via heat treatment. As 
disordered proteins are more resistant to heat, this approach enables the separation of 
disordered proteins from folded proteins. The proteins obtained can then be identified via mass 
spectrometry [94]. Alternatively, binding partners of IDPs can be identified based on their 
ability to protect the IDP from degradation. This may utilise the susceptibility of IDPs to 
degradation via the 20S proteasome. IDPs that are not protected will be degraded, while those 
that are protected, can then be identified [94].  
 
1.5.4 IDPs as drug targets 
IDPs make important contributions to cell signalling. As cell signalling processes often play 
roles in disease, IDPs are potential drug targets. However, their lack of structure has impeded 
drug design by traditional methods. Nonetheless, low molecular weight compounds have 
recently been designed that bind to the IDP nuclear protein 1, inhibiting its interactions with 
other proteins [112]. This study indicated that disordered interfaces between IDPs are potential 
drug targets. Drugs designed against IDPs may utilise the fact that the IDPs can fold upon 
binding; drugs are designed to bind to and stabilise the folded structure, preventing binding to 
native targets. Alternatively, inhibitors can stabilise the unfolded conformation, shifting the 
conformational equilibrium to the unfolded state, thus blocking further interactions [113]. If, 
however, IDPs remain unstructured, forming a fuzzy complex, drugs can be designed to 
compete for binding to same polypeptide region by also forming a fuzzy complex with the 
target protein [112]. This method has been utilised for the formation of small molecules 
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targeting the cell cycle regulating protein p27, which is entirely disordered, except for an N-
terminal domain that becomes ordered upon binding. The small molecules bound with high 
specificity to regions with aromatic rings (particularly Tyr and Trp) to form fuzzy structure 
activity relationships, inhibiting these residues of p27 from binding to Cdk2 [114].  
 
1.5.5 Engineering IDPs 
Attempts have been made to investigate the de novo design of artificial IDPs and to engineer 
IDRs to have new functions. This type of approach may be easier for IDPs than for folded 
proteins, as there are theoretically fewer specific sequence constraints for IDPs and more 
sequence redundancy, but this is yet to be confirmed. When designing artificial IDPs, disorder 
must be maintained [95]. Thus, IDPs may be viable targets for directed evolution techniques 
that maintain disorder while introducing new binding or other functionality [115].  
 
1.5.6 Stabilisation of intrinsically disordered proteins  
Previous studies in the laboratory have suggested that dimerisation domains within proteins 
may help in the stabilisation of intrinsically disordered regions in proteins. This was shown for 
CtIP, which contains a disordered domain that mediates binding to Lmo4 [116]. CtIP also 
contains a dimerization domain that was experimentally determined to be a coiled-coil [117]. 
The interaction between CtIP and Lmo4 was investigated using yeast two-hybrid analysis; both 
the disordered domain and the coiled-coil dimerization domain of CtIP were required to detect 
binding to Lmo4 in this assay. When the dimerization domain was replaced by a non-native 
coiled-coil—the leucine zipper of GCN4—the CtIP/Lmo4 interaction was still detected (Figure 
1.13), suggesting that the dimerization domain does not directly interact with Lmo4, but may 
instead stabilise the interaction or provide protection from degradation [61]. The disordered 
domain showed poor levels of expression when it was expressed in bacteria, presumably 
because it was rapidly degraded following bacterial expression. A second study found a similar 
occurrence with the protein Deaf1 [118]. Deaf1 contains a largely unstructured region, as well 
as a predicted coiled-coil, both of which needed to be present for an interaction between Deaf1 
and Lmo4 to be detected in yeast two-hybrid assays. Again, when the native coiled-coil domain 
from Deaf1 was replaced with the leucine zipper from GCN4, it was still possible to detect the 
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interaction [118]. This suggested that the presence of a dimerization domain might be a more 
generic method to stabilise IDP-mediated interactions and/or protect IDP from degradation.  
 
Figure 1.13 CtIP interactions with Lmo4. Schematic of CtIP constructs investigated for interaction 
with Lmo4 in yeast two-hybrid assays. Yeast two-hybrid assay carried out on low stringency media (-
LWH + 40 µg/mL X-α-gal). Green shows coiled-coil dimerisation domain of CtIP (residues 45-160), 
red shows LIM interaction domain of CtIP (residues 641-685) and blue shows leucine zipper 
dimerisation domain of GCN4 (residues 250-281). Dimerisation domains tethered via 20 residue 
glycine serine linker. Figure adapted from [61].  
 
1.6 Aims 
The purpose of this project was to investigate binding within the pentameric complex, 
expression levels of Ldb1 and Ldb1-like proteins, the binding of RLIM and Ldb1, and a 
potential method to stabilise IDPs. Each aim is detailed below. 
Aim 1: 
Investigating binding within the pentameric complex. The binding of Gata-1 to Lmo1 fused 
to Ldb1 was investigated using ITC (isothermal titration calorimetry). The potential binding of 
FOG in the pentameric complex was investigated using MALLS analysis. This work is 
discussed in chapter 3. 
Aim 2: 
Investigate mammalian Ldb1 and Ldb1-like proteins from various organisms. Ldb1 
expression levels were assayed in mammalian and bacterial expression systems. Truncated 
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constructs of Ldb1-like proteins, CeLdb1 and Adn1, were studied for their bacterial expression 
potential. This work is discussed in Chapter 3. 
Aim 3: 
Investigate the minimal binding domain of RLIM and Ldb1. Yeast two-hybrid analysis and 
pull-downs were used to investigate a direct interaction between RLIM and Ldb1. This work 
is discussed in Chapter 4. 
Aim 4: 
Generate a potential method for stabilising IDPs based on the incorporation of 
dimerization domains at the N- and/or C-termini of the IDP. The development of such an 
assay in the context of yeast two-hybrid analysis is described in Chapter 5. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2. Materials and Methods  27 
 
 
 
Chapter 2. Materials and Methods 
 
2.1 Materials 
2.1.1 Chemicals and Reagents 
Table 2.1 shows all chemicals and reagents used throughout this project. Solutions were 
prepared in MilliQ® water (MQW).   
TABLE 2.1 Chemicals and Reagents 
Chemical/Reagent Supplier 
2-log DNA ladder New England BioLabs (Beverly, MA) 
2-mercaptoethanol  Sigma-Aldrich (Castle Hill, NSW) 
3 × FLAG® peptide Apex Bio (Boston, MA) 
3-Amino-1,2,4-triazole (3-AT) Sigma-Aldrich (Castle Hill, NSW) 
5-bromo-4-chloro-3-indolyl-α-D-
galactopyranoside (X-α-gal) 
Astral Scientific (Caringbah, NSW) 
Acetic Acid Chem-Supply (Gillman, SA) 
Adenine Sigma-Aldrich (Castle Hill, NSW) 
Agarose Affymetrix (Santa Clara, CA) 
AmershamTM Hybond ECL Nitrocellulose 
Blotting Membrane 
GE Healthcare (Castle Hill, NSW) 
Ampicillin Sigma-Aldrich (Castle Hill, NSW) 
Anti-histidine antibody (trimethyl-histone 
H3 (lys 4)) 
Millipore (Bayswater, VIC) 
Anti-HRP antibody (donkey anti-mouse 
IgG-HRP) 
Santa Cruz Biotechnology (Dallas, 
TX) 
Bacterial peptone Affymetrix (Santa Clara, CA) 
Bacteriological agar Affymetrix (Santa Clara, CA) 
CaCl2 Ajax Finechem (Taren Point, NSW) 
Chloramphenicol Amresco (Solon, OH) 
Complete protease inhibitor cocktail 
tablets 
Roche Applied Science (Castle Hill, 
NSW) 
Complete Supplement Mixture (CSM) MP Biomedicals, LLC (Solon, OH, 
USA) 
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Coomassie Brilliant Blue Life Technologies (Mulgrave, VIC) 
Deoxyribonucleotide triphosphates 
(dNTPs) 
Roche Applied Science (Castle Hill, 
NSW) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (Castle Hill, NSW) 
Dithiothreitol (DTT) Sigma-Aldrich (Castle Hill, NSW) 
Ethanol Univar (Auburn, NSW) 
Ethylenediaminetetraacetic acid (EDTA) Ajax Finechem (Taren Point, NSW) 
Glucose Univar (Auburn, NSW) 
Glutathione Amerco (Solon, OH, USA) 
Glutathione sepharoseTM 4B beads GE Healthcare (Castle Hill, NSW)  
Glycerol Univar (Auburn, NSW) 
HA-Tag (6E2) Mouse mAb (HRP 
conjugate) 
Cell Signalling Technology (Danvers, 
MA) 
HCl Univar (Auburn, NSW) 
HEPES Astral Scientific (Caringbah, NSW) 
Histidine Sigma-Aldrich (Castle Hill, NSW) 
HydraGreen ACTGene (Piscataway, NJ) 
IGEPAL ® CA:630 Sigma-Aldrich (Castle Hill, NSW) 
Imidazole  Sigma-Aldrich (Castle Hill, NSW) 
Isopropyl β-D-thiogalactopyranoside 
(IPTG) 
Progen (Darra, Qld) 
KAc (Potassium acetate) Sigma-Aldrich (Castle Hill, NSW) 
KCl Ajax Finechem (Taren Point, NSW) 
KH2PO4 Chem-Supply (Gillman, SA) 
LiAc (Lithium acetate) Ajax Finechem (Taren Point, NSW) 
Lithium dodecyl sulfate (LDS) Sigma-Aldrich (Castle Hill, NSW) 
MagicMark Western standard Invitrogen (Mt Waverly, VIC) 
Mark 12 Unstained Protein Standard Invitrogen (Mt Waverly, VIC) 
MES buffer Invitrogen (Mt Waverly, VIC) 
Methanol Chem-Supply (Gillman, SA) 
MnCl2 Chem-Supply (Gillman, SA) 
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Monoclonal anti-FLAG® M2-Peroxidase 
(HRP) mouse antibody 
Sigma-Aldrich (Castle Hill, NSW) 
Monomeric bovine serum albumin New England Biolabs (Beverly, MA) 
Na2HPO4 Univar (Auburn, NSW) 
NaCl Chem-Supply (Gillman, SA) 
NaOH Chem-Supply (Gillman, SA) 
Nickel Beads (Ni-NTA beads) Invitrogen (Mt Waverly, VIC) 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich (Castle Hill, NSW) 
Polyethylene glycol, MW 4000 (PEG)  Hampton Research (Aliso Viejo, CA) 
Polyethylenimine (PEI) Sigma-Aldrich (Castle Hill, NSW) 
Salmon Sperm DNA Sigma-Aldrich (Castle Hill, NSW) 
Sepharose-S fast flow resin  Sigma Aldrich (Castle Hill, NSW) 
Sharp pre-stained protein standard Invitrogen (Mt Waverly, VIC) 
Sigma M2 beads Sigma-Aldrich (Castle Hill, NSW) 
SnakeSkin™ 10 kDa MWCO dialysis 
tubing 
Pierce Protein Biology Products 
(Rockford, IL) 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich (Castle Hill, NSW) 
Tris Chem-Supply (Gillman, SA) 
Tris(2-carboxyethyl)phosphine (TCEP) Soltec Ventures (Beverly, MA) 
Triton-X-100 Amresco (Solon, OH) 
Tryptone Oxoid (Hampshire, England) 
Tween-20 Amresco (Solon, OH) 
Western Lightning Plus ECL Perkin-Elmer (Waltham, MA) 
Yeast extract Amyl media (Dandenong, VIC) 
Yeast nitrogen base Difco (Detriot, MI) 
 
2.1.2 Enzymes 
Enzymes were used according to manufacturer’s instructions with buffers provided by 
manufacturer.  
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TABLE 2.2 Enzymes 
Enzyme Enzyme Commission 
Number (EC)  
Manufacturer  
BamH1 EC 3.1.21.4 New England BioLabs 
(Beverly, MA) 
EcoR1 EC 3.1.21.4 New England BioLabs 
(Beverly, MA) 
T5 exonuclease EC 3.1.11.3 New England BioLabs 
(Beverly, MA) 
HindIII EC 3.1.21.4 New England BioLabs 
(Beverly, MA) 
SmaI EC 3.1.21.4 New England BioLabs 
(Beverly, MA) 
KpnI EC 3.1.21.4 New England BioLabs 
(Beverly, MA) 
Pfu DNA polymerase EC 2.7.7.7 Jason Low (University of 
Sydney, Sydney) 
Phusion Hot Start DNA 
polymerase 
EC 2.7.7.7 Jason Low (University of 
Sydney, Sydney) 
Quick-Stick ligase EC 6.5.1.1 Bioline (Alexandria, NSW) 
T4 DNA ligase EC 6.5.1.1 New England BioLabs 
(Beverly, MA) 
TEV protease EC 3.4.21.5 James Walshe (University of 
Sydney, Sydney) 
Thermosensitive alkaline 
phosphatase 
EC 3.1.3.1 Promega (Madison, WI) 
Thrombin EC 3.4.21.5 Sigma-Aldrich (Castle Hill, 
NSW) 
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2.1.3 Bacterial strains, transformation buffers and culture media 
All plasmid and protein production was performed using strains of Escherichia Coli. Plasmid 
DNA amplified in E. coli DH5α (Bethesda Research Laboratories, Gaithersburg, MD) cells. 
Protein expression was carried out in E. coli BL21(DE3) (Integrated Sciences, Willoughby, 
NSW) cells and RosettaTM 2 (Merck, Dermstadt, Germany) cells. Bacterial genotypes are 
shown in Table 2.3. Transformations were carried out using KCM (100 mM KCl, 30 mM 
CaCl2, 50 mM MgCl2) or TFBI (30 mM KAc, 50 mM MnCl2, 100 mM KCl, 10 mM CaCl2, 
15% (v/v) glycerol, pH 5.8). Bacteria was grown either in Luria-Bertani (LB) broth (1% (w/v) 
peptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl) for liquid cultures, or on LB agar plates 
(1% (w/v) peptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, 1.5% (w/v) agar). Ampicillin 
(100 µg/mL) was added to LB broth and agar for all bacterial strains; chloramphenicol (34 
µg/mL) was also added for RosettaTM 2 cells. 
TABLE 2.3 Bacterial Strains 
Bacterial Strain Genotype 
E. coli DH5α F–, Φ80lacZΔM15, Δ(lacZYA-argF), U169, recA1, endA1, 
hsdR17, (rK–, mK+), phoA, supE44, λ–, thi-1, gyrA96, relA1 
E. coli BL21(DE3) F–, ompT, hsdSB (rB
–, mB
–), gal, dcm, (DE3) 
E. coli RosettaTM 2 F-, ompT, hsdSB (rB
– mB
–), gal, dcm, pRARE2 (CamR), (DE3) 
 
2.1.4 Yeast Strains and culture media 
Yeast two-hybrid analysis was carried out in the Saccharomyces cerevisiae strain, AH109 
(Clontech; MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1UAS-
GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2 URA3::MEL1UAS-MEL1TATA-LacZ MEL1).  
A list of media used for yeast analysis is shown in Table 2.4. All media were made up in MQW 
and autoclaved, with the exception of glucose, which was filter sterilised and added to cooled 
autoclaved media.  
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TABLE 2.4 Yeast medias 
Media Components 
Yeast peptone dextrose (YPD) liquid media 2% (w/v) tryptone, 1% (w/v) yeast extract, 
2% (w/v) glucose, 200 mg/L adenine, pH 5.8 
Yeast peptone dextrose (YPD) solid media 2% (w/v) tryptone, 1% (w/v) yeast extract, 
2% (w/v) glucose, 20 mg/L adenine, 
1.5% (w/v) agarose, pH 5.8 
Synthetic dextrose (SD) liquid media 0.67% (w/v) yeast nitrogen base, 2% (w/v) 
glucose, 6.1% (w/v) CSM 
 
2.2 Cloning of constructs 
2.2.1 Primers and plasmids 
Primers were ordered from Integrated DNA technologies (IDT, Coralville, IA, USA). Primers 
were designed for PCR and for Gibson Assembly cloning (See Appendix A for primers used). 
The yeast two-hybrid vectors pGAD10 (Clontech, CA, USA) and pGBT9 (Clontech, CA, 
USA), containing a Gal4 activation domain, and a Gal4 DNA binding domain, respectively, 
were used for yeast two-hybrid experiments. For the co-expression of Tal1/E47 and Gata-
1NC/Ldb1LID-Lmo1LIM2 a petDuet (EMD Millipore, MA, USA) vector was used. Tal1 or Gata-
1NC were cloned into MCSI for overexpression with an N-terminal 6 × histidine-tag. E47 or 
Ldb1LID-Lmo1LIM2 were cloned into MCSII for overexpression, without a tag. Gata-1NF, Lmo1-
Ldb1LID, CeLdb1, and Adn1, were overexpressed with N-terminal Glutathione-S-transferase 
(GST) tags using the pGEX-2T vector (GE Healthcare, Buckinghamshire, UK). CeLdb1 and 
Adn1 were also overexpressed with an N-terminal MBP tag using pMAL (New England 
Biolabs, MA, USA). Ldb1SA and GFP-USF1 were overexpressed with an N-terminal 6 × 
histidine tag fused to the GB1 protein in pHis-gb1. Mammalian expression was carried out 
using pHis-GB1 (yielding an N-terminal 6 × histidine-tag) or pcDNA3.1 providing either an 
N-terminal FLAG or HA tag.  
Plasmids containing Tal1/E47, Gata-1NC/Ldb1LID-Lmo1LIM2, Gata-1NF, Lmo1-Ldb1LID were 
provided by Dr Lorna Wilkinson-White, Ldb1SA constructs were provided by Dr Ingrid 
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MacIndoe. And CeLdb1 and Adn1 constructs provided by Jennifer Ting (all from the 
University of Sydney). 
2.2.2 Transformation protocol 
Plasmid DNA (~1 µg plasmid DNA or ligation mixture) was added to 50 µL KCM or TFBI 
and 50 µL competent DH5α cells. The cell suspension was incubated on ice for 20 min, 
followed by a 90 s heat shock at 42 °C (or 30 min at 37 °C for ligation mixtures) and cooled 
on ice for 60 s. Cells were then recovered in 200 µL sterile LB broth and incubated for 1 h (2 
h for ligation mix) at 37 °C. Cells were plated onto LB agar containing the appropriate 
antibiotic (100 µg mL-1 ampicillin for all plasmids used in all cell types, and an additional 34 
µg mL-1 chloramphenicol in Rosetta™ 2 cells). 
2.2.3 Gibson Assembly 
Gibson Assembly [119] was used to generate some DNA constructs for cloning. Primers were 
designed with a 30 bp overlap with the target vector. Vectors were linearised by restriction 
digestion with BamHI and EcoRI at 37 °C for 2 h and run on 2% (w/v) agarose gel TAE buffer 
(Tris-acetate buffer; 40 mM Tris, 40 mM Acetic Acid, 1 mM EDTA), stained with HydraGreen 
(ACT gene, Piscataway, NJ, US) and the fragment was excised using a PCR Clean Up and Gel 
Extraction Kit (Bioline, Alexandria, NSW). Fragments were amplified by PCR using Pfu DNA 
polymerase (1 U) and Pfu buffer (20 mM Tris (pH 8.8), 10 mM KCl, 10 mM (NH4)2SO4, 2 
mM MgSO4, 1% TritonX-100, 0.1 mg mL
-1 BSA), 0.1 mM dNTPs, 10% v/v DMSO, 400 nM 
primers and 50 ng template DNA. The PCR cycle involved denaturation at 95 °C for one min 
followed by 30 cycles of denaturation (95 °C for 1 min), annealing (55 °C for 1 min) and 
extension (72 °C for 1 min) and a further extension step at 72 °C for 10 min. The PCR product 
was run on a 2% (w/v) agarose gel and the band corresponding to the expected size was excised. 
Gibson Assembly reactions were set up with a 1:3 vector-to-insert molar ratio, made up to 5 
µL with MQW and 5 µL of Gibson Assembly® Master Mix (T4 DNA ligase, T5 exonuclease, 
Phusion Hot Start DNA polymerase and recommended buffer) was added. The solution was 
incubated at 50 °C for 1 h before being transformed into DH5α cells (as in section 2.2.2) and 
incubated at 37 ºC for ~16 h. 
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2.2.4 Screening of constructs 
Colonies were selected and the plasmids amplified and isolated using a Miniprep Kit (Bioline, 
Alexandria, NSW) as per manufacturer’s instructions. Transformants were screened for inserts 
via restriction enzyme digestion using BamHI and EcoRI, for 2 h at 37 °C. Digested constructs 
run on a 2% w/v agarose gel and constructs containing a band corresponding to the expected 
size confirmed via Sanger sequencing (AGRF, Sydney, NSW). 
 
2.2.5 Generation of full-length Ldb1 and Ldb2 
Total RNA was extracted from MEL cells using TRIsure reagent (Bioline, Alexandria, NSW) 
as per the manufacturer’s instructions. Reverse transcriptase PCR was used to generate cDNA 
from the extracted RNA using ProtoScript® II Reverse Transcriptase (New England Biolabs, 
Beverly, MA) according to the manufacturer’s instructions. Gene specific primers were used 
to generate the full length Ldb1 cDNA. A reverse transcriptase primer, which could anneal 50 
bp downstream from the Ldb1 stop codon, was used for the reverse transcriptase step and a 
reverse PCR primer, which was complementary to the end of the Ldb1 cDNA sequence, was 
used for PCR (Primers shown in appendix A). This PCR fragment was cloned into pGBT9 and 
pGAD10 using Gibson Assembly (Section 2.2.3).  
Extracted RNA from mouse (C57BI/6 strain) kidney cells was provided by David So Ri Jung 
and mouse (Sbno2 gene KO, WT) cerebellum cells by Taylor Syme (both from the University 
of Sydney). Reverse transcriptase PCR was used to generate cDNA from extracted RNA using 
ProtoScript® II Reverse Transcriptase (New England Biolabs, Beverly, MA) as per the 
manufacturer’s instructions. Gene specific primers were used to generate the full length Ldb2 
cDNA. A reverse transcriptase primer, which could anneal 50 bp downstream from the Ldb2 
stop codon was used as well as a reverse primer, which was complementary the end of the 
Ldb2 cDNA sequence (Primers shown in appendix A). PCR was used to amplify fragments 
using Phusion buffer and Ldb2 forward and reverse primers. PCR reactions were run on a 2% 
(w/v) agarose gel, but no fragments were observed.  
A synthetic gene fragment, sourced from Integrated DNA technologies (IDT, Coralville, IA, 
USA) corresponding to Ldb2 was cloned into pGBT9 and pGAD10. The gene fragment was 
designed with BamH1 and EcoR1 sites. A restriction digest using BamH1 and EcoR1 was 
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carried out at 37 °C for 2 h and run on a 2% (w/v) agarose gel and the fragment was excised 
and purified using a PCR Clean Up and Gel Extraction Kit (Bioline, Alexandria, NSW). The 
Ldb2 fragment was ligated into linearised pGBT9 and pGAD10 using Quick-Stick ligase and 
buffer followed by transformation into DH5α cells (Section 2.2.2).  
 
2.2.6 Generation of Ldb1 and RLIM constructs 
Ldb1 and Rlim DNA constructs were cloned into pcDNA3.1 using Gibson Assembly. 
Linearised pcDNA3.1 containing either a FLAG- or HA-tag was provided by Jason Low 
(University of Sydney).  Ldb1 and Rlim fragments corresponded to full-length constructs, as 
well as truncation mutants [Ldb1 (residues 259–375), RLIM (residues 306–426) and RLIM 
(residues 426–600)]. Fragments contained a 30 bp overlap with the vector and were amplified 
using PCR, and products were run on a 2% (w/v) agarose gel and extracted using a PCR Clean 
Up and Gel Extraction Kit (Bioline, Alexandria, NSW), and cloned into pcDNA3.1 using 
Gibson Assembly, as in Section 2.2.3.  
 
2.2.7 Generation of disordered domain constructs 
Constructs were designed such that a disordered domain [Ldb1LID (residues 300–339), Deaf1LID 
(residues 40–438) or RLIMBD (residues 306–426)] was tethered to one or two dimerisation 
domains [GCN4 (residues 250–281), CtIP (residues 45–150) or full length GST]. Tethers that 
linked dimerisation domains to the N-terminus of the disordered domain contained an HRV-
3C protease site, followed by a SmaI site, and tethers that linked dimerization domains to the 
C-terminus contained a TEV protease site, preceded a KpnI site, as shown in Figure 2.1. 
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Figure 2.1 Schematic of disordered domain constructs. Each construct was cloned into pGBT9 or 
pGAD10. Constructs were designed such that the disordered domain (yellow, LID; corresponding to 
Deaf1LID, Ldb1LID or RLIMBD) was tethered to a dimerisation domain [red, DD; GCN4 (residues 250–
281), CtIP (residues 45–150) or GST] via its N-terminus or C-terminus. When fused to the N-terminus 
of a LID (top), the dimerisation domain was tethered via an HRV-3C protease site followed by a SmaI 
site. When bound to the C-terminus of a LID (middle), the dimerisation domain was tethered via a TEV 
protease site preceeded by an KpnI site. Constructs were also made with dimerisation domains at both 
termini (bottom).  
 
Fragments were first PCR amplified and run on a 2% (w/v) agarose gel, and the fragments 
excised and purified. Constructs were cloned into pGBT9 or pGAD10 via Gibson Assembly 
(Section 2.2.3). Transformants were screened and confirmed as in Section 2.2.4.  
 
Constructs that could not be successfully cloned via Gibson assembly methods were assembled 
using overlap extension PCR methods. Fragments were PCR amplified (Section 2.2.3) and 
following gel extraction were subjected to a second round of PCR (overlap extension) to fuse 
the fragments by preparing the reaction as above, without primers, using 5 cycles of 
denaturation (95 °C for 1.5 min), annealing (55 °C for 50 s) and extension (72 °C for 1 min) 
plus a final extension step at 72 °C for 10 min. This was followed by a third round of PCR, 
with primers, to amplify the fragment. A PCR Clean Up and Gel Extraction Kit (Bioline, 
Alexandria, NSW) was used to purify the PCR-amplified fragments followed by simultaneous 
restriction enzyme digestion with BamH1 and EcoR1. The products of these digestion reactions 
were run on a 2% (w/v) agarose gel, stained with HydraGreen, visualised under UV light, and 
bands were excised and purified using a PCR Clean Up and Gel Extraction Kit (Bioline, 
Alexandria, NSW). Vectors were digested with BamH1 and EcoRI, and treated with 
thermosensitive alkaline phosphatase for 1 h at 37 °C, and then run on a 2% (w/v) agarose gel, 
excised and purified as for the insert. Inserts were ligated into these linearised pGBT9 and 
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pGAD10 vectors using Quick-Stick ligase and buffer followed by a transformation into DH5α 
cells.   
 
Some constructs were generated using a Zero Blunt™ TOPO™ (Invitrogen, Carlsbad, CA, US) 
cloning kit. Fragments were PCR amplified and gel extracted (Section 2.2.3), before being 
subjected to TOPO cloning, as per the manufacturer’s instructions. Transformants were 
screened and positive clones selected (Section 2.2.4) and used for further cloning. Constructs 
were subjected to restriction enzyme digestion using BamHI and EcoRI followed by ligation 
using Quick-Stick ligase into pGBT9 and pGAD10 and transformation into DH5α cells.  
 
The remainder of the constructs were cloned by Dr Neil Robertson as indicated in Chapter 5.  
 
2.3 Bacterial overexpression and purification 
2.3.1 Protein overexpression  
Plasmids were transformed (Section 2.2.2) into either RosettaTM 2 cells or BL21(DE3) cells 
and inoculated into 10 mL LB broth containing ampicillin (and chloramphenicol for RosettaTM 
2 cells) and incubated overnight at 37 °C with shaking. This cultured medium was diluted into 
LB broth with appropriate antibiotics to reach a final OD600 of 0.05 and incubated at 37 °C with 
shaking until OD600 reached 0.6–0.8 and overexpression was induced by the addition of 1 mM 
IPTG. Cells were then incubated a further 22 h at the temperature indicated in Table 2.6.  
TABLE 2.6 Growth temperatures following induction of protein expression. 
Construct Growth Temperature (°C) 
Gata-1NF 25 
Lmo1-Ldb1LID 22 
GFP-USF1 18 
Gata-1NC 22 
Ldb1LID-Lmo1LIM2 22 
Tal1/E47 22 
His-gb1-Ldb1 20 
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GST-CeLdb1_S; GST-CeLdb1_L; MBP-
CeLdb1_S; MBP-CeLdb1_L; GST-
Adn1_S; GST-Adn1_L; MBP-Adn1_L 
20 
 
Cells were harvested by centrifugation at 5 000 g at 4 °C for 20 min and stored at -20 °C until 
purification. 
 
2.3.2 Protein Purification Buffers 
Cell pellets were resuspended in lysis buffer (Table 2.7) and sonicated with 6 × 30 s bursts to 
lyse the cells followed by centrifugation at 13 000 g for 20 min to separate the soluble and 
insoluble fractions. Subsequent purification steps used the buffers described in Table 2.7.  
TABLE 2.7 Buffer components for protein purification. 
Construct Buffer Components 
Gata-1NF Lysis buffer: 20 mM Tris, 500 mM NaCl, 0.1% (v/v) 2-
mercaptoethanol, 0.2 mM PMSF, pH 7.4. 
Wash buffer: 20 mM Tris, 500 mM NaCl, 10% (v/v) glycerol, 
0.1% (v/v) 2-mercaptoethanol, 0.2 mM PMSF, pH 7.4. 
Equilibration buffer: 20 mM Tris, 150 mM NaCl, 3 mM 
CaCl2, 0.1% (v/v) 2-mercaptoethanol, pH 7.4. 
Elution buffer: 20 mM Tris, 150 mM NaCl, 3 mM CaCl2, 20 
mM glutathione, 0.1% (v/v) 2-mercaptoethanol, pH 7.4. 
Cation exchange buffer: 20 mM Tris, 1 mM DTT, pH 7.4; 0–
1 M NaCl. 
Size-exclusion buffer: 20 mM Tris, 100 mM NaCl, 1 mM 
TCEP, pH 7. 
Lmo1-Ldb1LID Lysis buffer: 50 mM Tris, 50 mM NaCl, 0.1% (v/v) 2-
mercaptoethanol, 0.2 mM PMSF, pH 8. 
Wash buffer: 50 mM Tris, 50 mM NaCl, 10% (v/v) glycerol, 
0.1% (v/v) 2-mercaptoethanol, 0.2 mM PMSF, pH 8. 
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Equilibration buffer: 20 mM Tris, 150 mM NaCl, 3 mM 
CaCl2, 0.1% (v/v) 2-mercaptoethanol, pH 8. 
Elution buffer: 20 mM Tris, 150 mM NaCl, 3 mM CaCl2, 20 
mM glutathione, 0.1% (v/v) 2-mercaptoethanol, pH 8. 
Size exclusion buffer: 20 mM Tris, 100 mM NaCl, 1 mM 
TCEP, pH 7. 
GFP-USF1 Lysis buffer: 50 mM Tris, 150 mM NaCl, 0.1% (v/v) 2-
mercaptoethanol, 0.2 mM PMSF, pH 8. 
Size exclusion buffer: 50 mM Tris, 100 mM NaCl, 1 mM 
TCEP, pH 7. 
Gata-1NC/ Ldb1LID-
Lmo1LIM2/ Tal1/E47 
Lysis buffer: 50 mM Tris, 100 mM NaCl, 0.1% (v/v) 2-
mercaptoethanol, 0.2 mM PMSF, pH 7.2. 
Cation exchange wash buffer: 50 mM Tris, 100 mM NaCl, 
0.1% (v/v) 2-mercaptoethanol, 0.2 mM PMSF, 1 × Complete 
protease inhibitor, pH 7. 
Nickel wash buffer: 20 mM Tris, 400 mM NaCl, 50 mM 
Imidazole, 0.1% (v/v) 2-mercaptoethanol, 0.2 mM PMSF, pH 7. 
Nickel elution buffer: 20 mM Tris, 400 mM NaCl, 0.1% (v/v) 
2-mercaptoethanol, 0.2 mM PMSF, 1 × Complete protease 
inhibitor, pH 7. 
His-GB1-Ldb1SA Lysis/wash buffer: 20 mM Tris, 10 mM Imidazole, 300 mM 
NaCl, 0.1% (v/v) 2-mercaptoethanol, 0.2 mM PMSF, pH 8. 
Dialysis buffer: 20 mM MES, 30 mM NaCl, 1 mM TCEP, pH 
6.5. 
Anion exchange buffer: 20 mM MES, 1 mM TCEP, 0–1 M 
NaCl, pH 6.5. 
GST-CeLdb1_S; GST-
CeLdb1_L 
Lysis buffer: 50 mM Tris, 150 mM NaCl, 0.1% (v/v) 2-
mercaptoethanol, 0.2 mM PMSF, pH 7. 
Wash buffer: 50 mM Tris, 150 mM NaCl, 10 % (v/v) glycerol, 
0.1% (v/v) 2-mercaptoethanol, 0.2 mM PMSF, pH 7. 
 
Chapter 2. Materials and Methods  40 
 
 
 
MBP-CeLdb1_S; MBP-
CeLdb1_L; MBP-
Adn1_L 
Lysis buffer: 50 mM Tris, 150 mM NaCl, 0.1% (v/v) 2-
mercaptoethanol, 0.2 mM PMSF, pH 7.5. 
 
GST-Adn1_S; GST-
Adn1_L 
Lysis buffer: 50 mM Tris, 150 mM NaCl, 0.1% (v/v) 2-
mercaptoethanol, 0.2 mM PMSF, pH 8. 
Wash buffer: 50 mM Tris, 150 mM NaCl, 10 % (v/v) glycerol, 
0.1% (v/v) 2-mercaptoethanol, 0.2 mM PMSF, pH 7. 
 
2.3.3 Glutathione-S-transferase affinity chromatography 
The soluble fraction containing GST tagged proteins was incubated with Glutathione-
Sepharose® 4B beads (5 mL per 3 L bacterial cell culture in a BioRad Econo-Column; GE 
Healthcare Life Sciences) that had been previously washed with 10 column volumes (CV) of 
MQW and equilibrated with 10 CV of lysis buffer, and incubated at 4 °C with rocking for 45 
min. The resin was subsequently washed with 5 CV of wash buffer. The resin was washed in 
equilibration buffer, prior to elution of the protein in 6×1-CV elution fractions, alternating 
between elution buffer and equilibration buffer, to prevent protein precipitation. These 
fractions were analysed by SDS-PAGE in 1×MES running buffer (Invitrogen, Mt Waverly, 
VIC), using Bolt Bis-Tris Plus gels in recommended gel tanks (Thermo Scientific, Rockford, 
IL, USA). SDS-PAGE was run for 24 min at 200 V, followed by staining with Coomassie 
Brilliant Blue for 20 min and destaining in water overnight. Fractions were incubated overnight 
with 2 U/ µL thrombin protease at 4 °C with agitation to remove the GST-tag and samples were 
analysed by SDS-PAGE gel. Fractions containing the cleaved protein were pooled and if not 
used or further purified immediately were stored at 4 ºC. 
 
2.3.4 Cation exchange chromatography 
Cation exchange chromatography was carried out using a BioLogic DuoFlow (BioRad, 
Hercules, CA) chromatography system fitted with a UnoS1 cation exchange column (BioRad, 
Hercules, CA) in cation exchange buffer. Approximately 5 mL of partially purified protein 
sample was injected onto the column. Protein was eluted in 1 mL fractions with a 0–1 M NaCl 
gradient over 20 min at 2 mL/min. Fractions were analysed by SDS-PAGE and those 
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containing the highest and most pure levels of the target protein were pooled and if not used or 
further purified immediately were stored at 4 ºC. 
 
2.3.5 Size exclusion chromatography 
Size exclusion chromatography was carried out on a BioLogic DuoFlow (BioRad, Hercules, 
CA) using a HiLoad™ 16/600 Superdex S75 pg size exclusion column (GE Healthcare) in size 
exclusion buffer. Approximately 5 mL of partially purified protein sample was injected onto 
the column. A flow rate of 1 mL/min over 120 min was used, with 1 mL fractions eluted.  
Eluted fractions were analysed by SDS-PAGE, and cleanest fractions containing protein were 
pooled and snap frozen for storage at -80 ºC. 
 
2.3.6 Ni-NTA purification 
The soluble lysate or partially purified samples of His-tagged proteins was applied to Ni-NTA 
beads (2 mL per L culture volume, Invitrogen) that had been washed in 10 CV of MQW and 
equilibrated with 10 CV of lysis buffer, and incubated at 4 °C with rocking for 45 min. Beads 
were washed 3 times in lysis buffer (5 CV) containing 20 mM imidazole, followed by elution 
with increasing imidazole concentrations (20 mM to 1 M in wash buffer), usually 8×1 CV. 
 
2.3.7 Dialysis 
Proteins were dialyzed overnight at 4 °C, with agitation into appropriate buffer using 
SnakeSkin Dialysis Tubing (10 kDa molecular weight cut off; Pierce Protein Biology Products, 
Rockford IL).  
 
2.3.8 Purification protocols 
Gata-1NF was expressed as a GST-Gata-1NF, subjected to GST-affinity chromatography 
(Section 2.3.3), dialyzed overnight (Section 2.3.7) into cation exchange buffer to remove salt, 
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followed by cation exchange chromatography (section 2.3.4) and size exclusion 
chromatography (Section 2.3.5). 
Lmo1-Ldb1LID was expressed as GST-Lmo1-Ldb1LID, subjected to GST-affinity 
chromatography as described in section 2.3.3, except that the GST-tag was removed by 
incubation with 2 U/ µL thrombin protease for 2 h, with samples taken every 30 min at 4 °C 
with agitation. The protein was further purified by size exclusion chromatography and snap 
frozen for storage at -20 ºC. 
GFP-USF1 was expressed as 6xHis-GFP-USF1 and purified by Ni-NTA purification (Section 
2.3.6), dialyzed overnight (Section 2.3.7) into size exclusion buffer to remove imidazole, and 
size-exclusion chromatography (Section 2.3.5). 
Tal1/E47 and Gata-1NC/Ldb1LID-Lmo1LIM2 were co-purified, with soluble lysates from the 
co-expression of Tal1/E47 with that for the co-expression of Gata-1NC/Ldb1LID-Lmo1LIM2 were 
combined in a 1:1 ratio and applied to Sepharose-S fast flow resin (1 mL per L culture volume; 
Sigma Aldrich) that had previously been washed in 10 CV of MQW and equilibrated with 10 
CV of lysis buffer. The resin was washed in 5 CV of wash buffer and protein was eluted in 
wash buffer with increasing NaCl concentrations (0.4–1 M NaCl; pH 7.5; 5×1 CV). Elution 
fractions were analysed by SDS-PAGE gel and those containing the highest and most pure 
levels of the target protein were pooled and subjected to Ni-NTA purification (Section 2.3.6), 
except that beads were washed with 2 CV wash buffer and eluted in elution buffer containing 
increasing imidazole (100–600 mM; 5×1 CV).  
His-GB1-Ldb1SA was purified by Ni-NTA purification but not eluted with imidazole-
containing buffer. Beads were resuspended in 1 CV of lysis buffer and incubated with 1 U/ µL 
TEV protease overnight at room temperature without agitation to remove the His-GB1 tag. 
Cleaved protein was eluted in lysis buffer (5×1 CV) and fractions analysed by SDS-PAGE with 
those containing the highest and most pure levels of the target protein pooled and dialysed 
overnight into dialysis buffer, followed by two further rounds of dialysis for 2 h each. Anion 
exchange chromatography was carried out using the BioLogic DuoFlow (BioRad, Hercules, 
CA) using a UnoQ1 anion exchange column (BioRad, Hercules, CA) in anion exchange buffer 
with protein being eluted with a 0–1 M NaCl gradient over 20 min. Eluted fractions were 
analysed by SDS-PAGE, and those containing the highest and most pure levels of the target 
protein were pooled. 
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GST-tagged CeLdb1 and Adn1, were immobilised onto Glutathione-Sepharose® 4B beads 
(0.1 mL beads) following the basic protocol for GST-affinity purification on a small scale, but 
samples were not eluted from the beads. MBP-tagged CeLdb1 and Adn1 was treated the same 
way, but immobilised onto Amylose resin (0.1 mL; New England Biolabs). The beads were 
washed with 5 CV of lysis buffer and bead samples were analysed by SDS-PAGE.  
Protein and DNA sample concentrations were determined using UV-spectrophotometry on a 
Nanodrop ND-100 spectrophotometer (Thermo Scientific; Rockford, IL, USA) using 
extinction coefficients shown in Table 2.8. 
TABLE 2.8 Extinction coefficients of purified proteins. Extinction coefficients estimated 
based on sequence ExPASy ProtPram 
Protein construct Extinction coefficient (M-1 cm-1) 
Gata-1NF 8 480 
Lmo1-Ldb1LID 29 910 
GFP-USF1 42 290 
Gata-1NC/ Ldb1LID-Lmo1LIM2/ Tal1/E47 36 900 
His-GB1-Ldb1SA 33 920 
  
2.4 Mammalian overexpression and purification 
2.4.1 Protein overexpression  
Ldb1 and RLIM, and their truncation mutants, as well as FLAG-tagged Ldb1SA and His-GB1-
tagged Ldb1SA were expressed in HEK 293 EXPI cells in EXPI 293 media (Thermo Scientific, 
Rockford, IL, USA). Cells were grown at 37 °C in an orbital shaker with agitation at 130 rpm 
at 5% CO2. Cells were diluted to 1.5 × 10
6 cells/mL per transfection. Cells were transfected 
with 2 µg DNA/mL of culture in PBS and vortexed for 3 s and added to 1 mg/mL filter-
sterilised PEI and vortexed vigorously. The DNA mixture was incubated for 20 min at room 
temperature prior to addition to the cells. Following co-transfection, cells were grown for a 
further 72 h. Cells were harvested by centrifugation (300 g for 5 min), followed by washing 
with PBS. Cells were snap frozen and stored at -80 °C prior to further analysis.  
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Expression levels were assayed by resuspending the cell pellet in PBS and LDS and boiling for 
5 min prior to western blot analysis (Section 2.4.3).  
 
2.4.2 Mammalian pull-down assays 
Cell pellets were resuspended in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% (v/v) Triton-
X-100, 1 mM PMSF, 1×Complete, 0.2 mM DTT, pH 7.9), prior to sonication at 2×0.5 s bursts 
to lyse the cells, followed by incubation on ice for 45 min and centrifugation at 18 000 g for 
10 min at 4 °C. The soluble fraction/clarified lysate was used for pull-down assays. 
 
The clarified cell lysate was incubated with Sigma M2 beads (Sigma-Aldrich, Castle Hill, 
NSW; previously washed 3 times in TBS; 50 mM Tris, 150 mM NaCl, pH 7.9) overnight at 4 
°C with rotation. Beads were washed in TBS containing 0.5% (v/v) IGEPAL® CA:630 (Sigma-
Aldrich, Castle Hill, NSW) and 0.2 mM DTT, gently vortexed then centrifuged at 2000 g for 
5 min. The wash step was completed four more times. 3×FLAG® peptide (Apex Bio (Boston, 
MA); in 10 mM HEPES, 150 mM NaCl, pH 7.5) was added to beads and rotated for 30 min at 
4 °C. The beads were centrifuged at 2000 g for 5 min and the supernatant collected as the 
elution fraction. Samples were analysed via western blot analysis (see below).   
 
2.4.3 Western Blot Analysis 
Proteins in the samples were separated by SDS-PAGE gel alongside Sharp pre-stained protein 
and MagicMarkTM Western standards and then transferred onto AmershamTM Hybond ECL 
Nitrocellulose Blotting Membrane (GE Healthcare, Castle Hill, NSW) using a Bolt Module 
Apparatus (Life Technologies) in transfer buffer (1×MES running buffer (Invitrogen, Mt 
Waverly, VIC), 20% (v/v) methanol) at 10 volts for 60 min. Following transfer, the membrane 
was washed three times in 1×PBS-T (1×PBS (130 mM NaCl, 2.6 mM KCl, 10 mM Na2HPO4, 
1.76 mM KH2PO4), 0.1% (v/v) Tween-20). All further wash and incubation solutions contained 
1×PBS-T and were conducted at room temperature. The membrane was blocked in 5% (w/v) 
skim milk for 1 h and washed three times before incubating with appropriate antibodies (Table 
2.9) for 1 h. The immobilised antibody was visualised using chemiluminescence generated by 
Western Lightning Plus ECL (Perkin-Elmer, Waltham, MA) on a C-DiGit Chemiluminescent 
Western Blot Scanner (LI-COR, Lincoln, NE).  
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TABLE 2.9 Antibodies used for western blot visualisation 
Construct Primary Antibody Secondary Antibody 
FLAG-tagged Anti-FLAG® M2-
Peroxidase (HRP) antibody 
(mouse) 
N/A 
HA-tagged HA-Tag (6E2) Mouse mAb 
(HRP conjugate) 
N/A 
His-gb1 tagged Anti-histidine (trimethyl-
histone HE (lys 4)) 
Anti-HRP (donkey anti-
mouse, IgG-HRP) 
 
2.5 Multi angle laser light scattering (MALLS) 
The protein subcomplex Tal1/E47/Gata-1NC/Ldb1LID-Lmo1LIM2 was buffer exchanged into 
MALLS buffer (20 mM Tris, 100 mM NaCl, 1 mM TCEP, pH 7) using PD-10 Desalting 
columns (2.5 mL, GE Healthcare, Castle Hill, NSW). The proteins were filtered using a 
Millex® Sterile 0.2 µm syringe filter (Millipore, Bayswater, VIC) to remove precipitate, 
followed by determination of concentration (Section 2.3.8). dsDNA (containing an E-box DNA 
site and GATA DNA side; prepared and supplied by Dr Lorna Wilkinson-White) was added at 
a 1.2-fold molar excess, and filtered as above. GFP-USF1 was also added at a 1.2-fold molar 
excess. The assembled complex was concentrated in Millipore® Amicon® Ultra-15 
Centrifugal Filter Concentrators (3 kDa MWCO; Bayswater, VIC) at 16 °C as per the 
Manufacturer’s instructions. 
Protein samples were applied to a Sepharose 12 10/300 GL column (GE Healthcare, Castle 
Hill, NSW) in MALLS buffer (20 mM Tris, 100 mM NaCl, 1 mM TCEP, pH 7) which was 
positioned in line with MiniDAWNTM TREOS multi angle light scattering and Optilab T-rEX 
differential reactive index detectors (Wyatt Technology, Santa Barbara, CA) on an AKTA Fast 
Protein Liquid Chromatography system (GE Healthcare, Castle Hill, NSW). The average 
molecular weights of the protein were calculated using the supplied ASTRA 6.1 software 
(Wyatt Software, Santa Barbara, CA). Monomeric bovine serum albumin was used as a control.   
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2.6 Isothermal Titration Calorimetry (ITC) 
Purified Gata-1NF and Lmo1-Ldb1LID were dialysed overnight at 4 ºC into ITC buffer (20 mM 
MES, 100 mM NaCl, 1 mM TCEP, pH 6.5) and the protein concentration determined (Section 
2.3.8). Samples were filtered using a Millex® Sterile 0.2 µm syringe filter (Millipore, 
Bayswater, VIC).  
Experiments were performed by titrating Gata-1NF into Lmo1-Ldb1LID using an ITC
200 TM 
microcalorimeter (MicroCal Inc., Northhampton, MA, USA). The temperature was maintained 
at 20 °C with the reference power set to 2 µcal s-1. Injection volumes were set at 2 µL with a 
duration of 4 s with intervals between injections of 120 s. A control experiment was also carried 
out by titrating Gata-1NF into buffer, which was used to correct the data. Data was analysed 
using the Origin 7 ITC data analysis software package (MicroCal Inc., Northhampton, MA, 
USA), and the association constant (KA) and stoichiometric ratio (n) determined by fitting the 
data by a single site binding model.  
 
2.7 Yeast Two-Hybrid Analysis 
2.7.1 Competent yeast preparation 
Yeast was grown in rich media, YPD, overnight at 30 °C, with shaking at 220 rpm. Cells were 
centrifuged at 1000 g for 5 min, cell pellets were then resuspended in sterile water and 
centrifuged again at 1000 g for 5 min. Cell pellet was resuspended in 1×TE/LiAc (10 mM Tris 
(pH 8.0), 1 mM EDTA, 100 mM LiAc (pH 7.5)).  
 
2.7.2 Yeast Transformation 
Aliquots (1 µL) of each plasmid (pGBT9/pGAD10) was added to 100 µL of competent yeast 
and 10 µL of carrier DNA (salmon sperm DNA). Sterile PEG/LiAc (600 µL; 40% (w/v) PEG, 
100 mM LiAc (pH 7.5), 10 mM Tris (pH 8.0), 1 mM EDTA) was added and the solution was 
vortexed, followed by incubation at 30 °C with shaking at 200 rpm for 30 min. Following 
incubation, 70 µL of DMSO was added and the cells were heat shocked at 42 °C for 15 min, 
with gentle mixing every 5 min. Cells were then chilled on ice for 1-2 min before centrifugation 
for 5 s at 7000 g. Supernatant was removed and pellet resuspended in 300 µL 1×TE (10 mM 
Tris (pH 8.0), 1 mM EDTA). Cells were then plated onto SD solid media (-L-W, lacking 
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leucine and tryptophan, with added histidine (20 mg/L) and adenine (20 mg/L)). Plates were 
incubated at 30 °C for 72 h.  
 
2.7.3 Yeast spot test 
Liquid SD media supplemented with 20 mg/L histidine and 10 mg/L adenine was inoculated 
with yeast transformants and grown overnight at 30 °C with shaking at 220 rpm. Cultures were 
then diluted to an OD600 of 0.2 with sterile MQW, and two 1-in-10 serial dilutions were 
performed. Aliquots (2 µL) of each dilution condition was spotted onto SD growth and 
selection plates and grown at 30 °C for 72 h.  
 SD growth plate (-L-W): 20 mg/L histidine, 20 mg/L adenine 
SD selection (-L-W-H +3-AT): 20 mg/L adenine, 40 µg/mL X-α-gal, 0.5 mM 3-AT
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Chapter 3. Investigation of interactions within the Tal1/E2a/Lmo/Ldb/Gata pentameric 
complex 
 
One of the key haematopoietic transcriptional complexes involved in the activation of β-globin 
genes is the pentameric complex, comprising Tal1, E2A, Lmo2, Gata-1 and Ldb1 [45] as 
described in detail in Chapter 1 (Section 1.1.3 and Section 1.2). In brief, Tal1 and E12 form a 
bHLH heterodimer, which binds DNA at E-box sites (CANNTG) [120]. Gata-1 binds DNA at 
WGATAR sites via the C-terminal finger (Gata-1CF) [121], which leaves the N-terminal finger 
(Gata-1NF) free to bind proteins. Lmo2 has been shown to simultaneously bind Gata-1 and 
Tal1/E12, bridging the DNA-binding components of complex and thereby assisting binding to 
bi-partite E-box/GATA sites. Gata-1NF binds the Lmo2LIM2 domain with a modest affinity (KA 
= 5 × 104 M-1 [75]. Ldb1 binds both LIM domains of Lmo2 via its LIM interaction domain 
(Ldb1LID) [57, 63]. 
Structures of the various components have been solved. Overlaying of the structures of 
Tal1/E47/Lmo2-Ldb1 bound to DNA, and the double-tethered Ldb1LID-Lmo1LIM2-Gata-1NF, as 
discussed in Chapter 1 (Section 1.2.6; Figure 1.5) shows the possible orientation of these 
proteins in the pentameric complex. Combining this with the Gata-1NF/USF-1 complex 
suggested that a FOG1 zinc finger may fit between Tal1 and Gata-1NF in the complex (Figure 
3.1). This arrangement could enhance the stability of FOG-Gata-1 interactions and promoting 
additional interactions within the larger complex.  
Ldb1 self-associates via its N-terminal self-association domain to form a dimer. The formation 
of this dimer facilitates chromatin looping, allowing β-globin activation [28]. Several proteins 
have been discovered which may be related to Ldb1. These include Ldb1 from C. elegans and 
Adn1 from S. pombe. As discussed in Section 1.3.1, both of these proteins contain a region 
with similarity to Ldb1SA. 
This Chapter explores the ability of FOG1 fingers to take part in a larger transcriptional 
complex, and the expression properties of Ldb1-like proteins.  
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Figure 3.1 Alignment of Ldb1LID-Lmo1LIM2-Gata-1NF, Gata-1NF/USF1 and E47/Tal1/Ldb1-Lmo2 
structures. A. Structural Alignment of DNA/Tal1/E47/Lmo2-Ldb1LID, Ldb1LID-Lmo1LIM2-Gata-1NF 
and Gata-1NF/USF1. Zinc is shown as grey spheres (Alignment by J Matthews) B. Schematic of 
complex. Ldb1 (orange) binds Lmo1 (dark blue) which simultaneously binds Tal1 (green) and E47 
(yellow) and Gata-1 (red). Gata-1 binds USF1 (cyan). Gata-1 and Tal1/E47 bind DNA (A. white B. 
black) at WGATAR and CANNTG sites respectively.  
 
3.1 Constructs used in this Chapter 
Various constructs were used for in the experiments described in this chapter, all of which are 
defined in Table 3.1.  
TABLE 3.1 Details of constructs used 
Construct Tag Protein Protein Species 
Gata-1NF N/A Gata-1 residues 200–254  Mus Musculus  
Lmo1-Ldb1LID N/A Lmo1 residues 18–150; 13 
residue G-S linker; Ldb1 
residues 295–339 
Mus Musculus 
GFP-USF1 His-gb1 GFP; 11 residue G-S linker; 
USF1 residues 202–235 
Drosophila 
Melanogaster 
Tal1 His-gb1 Tal1 residues 186–246 Mus musculus 
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E47 N/A TCF3 Isoform E47 residues 
544–603 
Mus musculus 
Gata-1NC N/A Gata-1 residues 200–318 Mus musculus 
Ldb1LID-Lmo1LIM2 N/A Ldb1 residues 295–313; 13 
residue G-S linker; Lmo1 
residues 77–150 
Mus musculus 
His-gb1-Ldb1 His-gb1 Ldb1 residues 14–200 Mus musculus 
FLAG-Ldb1 FLAG Ldb1 residues 1–200 Mus musculus 
HA-Ldb1 HA Ldb1 residues 1-200 Mus musculus 
GST-CeLdb1_L GST Ldb1 residues 2–369 Caenorhabditis 
elegans 
GST-CeLdb1_S GST Ldb1 residues 76–282 Caenorhabditis 
elegans 
MBP-CeLdb1_L MBP Ldb1 residues 2–369 Caenorhabditis 
elegans 
MBP-CeLdb1_S MBP Ldb1 residues 76–282 Caenorhabditis 
elegans 
GST-Adn1_L GST Adn1 residues 2–277 Schizosaccharomyces 
pombe 
GST-Adn1_S GST Adn1 residues 2–205 Schizosaccharomyces 
pombe 
MBP-Adn1_L MBP Adn1 residues 2–277 Schizosaccharomyces 
pombe 
 
3.2 Investigation of the binding affinity of Gata-1:Lmo1 Binding Affinity  
A wider aim in the laboratory was to determine structures of components of the transcriptional 
complex. To that end, a tethered construct containing Ldb1LID-Lmo2LIM2-Gata-1NF was 
expressed and purified. Unfortunately, NMR analysis indicated that the residues at the 
Lmo2:Gata1 interface were in intermediate exchange, which hampered structure 
determination. As such, other Lmo proteins were tested to establish if they could interact with 
Gata-1NF. GST-pull-down experiments were used to show that Lmo1-Ldb1LID, Lmo2-Ldb1LID 
and Lmo3-Ldb1LID were able to bind both Gata-1NF and Tal1/E47 heterodimers, whereas 
Chapter 3. Investigation of interactions within the Tal1/E2a/Lmo/Ldb/Gata pentameric complex 51 
 
 
 
Lmo4-Ldb1LID did not [122]. As a result, Lmo1 was selected for further study because it can 
also induce T-ALL and is generally considered to substitute for Lmo2 in Gata-1-containing 
transcriptional complexes [122]. In this chapter experiments are described to further 
characterise the Lmo1:Gata-1NF interaction by quantification of the binding affinity.  
 
3.2.1 Expression and purification of constructs 
Gata-1NF 
Gata-1NF, the N-terminal finger of Gata-1 (comprising residues 200–254 of the mouse protein) 
was expressed using 0.4 mM IPTG induction in BL21(DE3) E. coli cells and purified by 
glutathione (GSH) affinity chromatography and treatment with thrombin to remove the GST 
tag, prior to cation exchange chromatography, as described in section 2.3 (Figure 3.2). The 
largely soluble GST-Gata1NF protein was purified by GST-chromatography (Figure 3.2A) and 
each elution fraction from the GSH resin was separately treated with thrombin resulting in 
~50% removal of the GST-tag as judged by SDS-PAGE (Figure 3.2B). Gata-1NF was not fully 
separated from GST and uncleaved GST-Gata-1NF after cation exchange chromatography 
(Figure 3.2C). Thus, the samples were submitted to size-exclusion chromatography (Figure 
3.2D). This yielded approximately 5 mL of 50 µM Gata-1NF from 3 L of expression culture. 
Even following size-exclusion chromatography fractions still contained small amounts of 
uncleaved GST-Gata-1NF protein as seen by SDS-PAGE. 
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Figure 3.2 SDS-PAGE analysis of Gata-1NF purification. Gata-1NF expressed in BL21(DE3) cells 
grown at 37 °C before 0.4 mM IPTG induction at OD600 nm ~0.6 followed by A. GSH-affinity 
purification. Soluble lysate was incubated on GSH beads, followed by washing and elution with 20 mM 
glutathione in 20 mM Tris, 150 mM NaCl, 3 mM CaCl2, 0.1% v/v 2-mercaptoethanol, pH 7.4. B. 
Thrombin cleavage. Each fraction of GST-Gata-1NF was treated overnight with 200 U thrombin to 
remove the GST-tag. C. Cation exchange chromatography. All fractions of cleaved protein were pooled 
and subjected to cation exchange chromatography using a UnoS column in 20 mM Tris, 1 mM DTT, 
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pH 7.4, with a 0–1 M NaCl gradient, with fractions collected from 300–600 mM NaCl. D. Size-
exclusion chromatography. Fractions from cation exchange chromatography were pooled and 
concentrated prior to being subjected to size exclusion chromatography on a S75 column in 20 mM 
Tris, 100 mM NaCl, 1 mM TCEP, pH 7.  
Lmo1-Ldb1LID 
Lmo1 is insoluble and prone to aggregation, and thus was tethered to Ldb1LID for expression 
[56, 57]. The Lmo1-Ldb1LID construct used for this assay contained both LIM domains (LIM1 
and LIM2) of Lmo1 and the full Ldb1LID (residues 295–339). The fusion construct was 
expressed and purified as described in section 2.3 (Figure 3.3). The construct was expressed in 
BL21(DE3) E. coli cells using 0.4 mM IPTG induction, followed by GSH affinity 
chromatography and on bead thrombin cleavage (Figure 3.3A). Protein was further purified by 
size exclusion chromatography, where it eluted in two peaks of high purity. Fractions from 
each peak were pooled together and kept for further analysis (20 mL of 41 µM Lmo1-Ldb1LID 
from 6 L of expression culture). 
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Figure 3.3 SDS-PAGE analysis of Lmo1-Ldb1LID purification. BL21(DE3) cells were grown at 37 
°C before induction with 0.4 mM IPTG at OD600 nm ~ 0.6 for 22 h at 22 °C.  A. GSH-Affinity 
purification. Soluble cell lysate was applied to GSH resin, followed by a wash step and cleavage with 
thrombin (200 U) in 20 mM Tris, 150 mM NaCl, 3 mM CaCl2, 0.1% v/v 2-mercaptoethanol, pH 8 to 
release the untagged protein. B. Size exclusion chromatography. Cleaved protein was concentrated and 
run on S75 column in 20 mM Tris, 100 mM NaCl, 1 mM TCEP, pH 7.  
  
3.2.2 Binding of Gata-1NF to Lmo1-Ldb1LID 
Isothermal titration calorimetry (ITC) was used to determine binding affinity of Gata-1NF for 
Lmo1-Ldb1LID (Figure 3.4) as described in section 2.6. Gata-1NF was separately titrated into 
two slightly different concentrations of Lmo1-Ldb1LID, both from the same batch of purified 
protein. The signal to noise in the experiment was relatively low, suggesting a low enthalpy 
under the conditions of the experiment. When Lmo1-Ldb1LID was used at 26 µM, it was noted 
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that the stoichiometric ratio was lower than expected (0.5:1, rather than 1:1) (Table 3.2), which 
likely arises from the low signal-to-noise and/or errors in estimation of protein concentrations. 
When using a 19 µM solution, the stochiometric ratio was 1.1:1.  Binding affinity is less 
sensitive to errors in protein concentration than stoichiometry, so those values from the two 
experiments were consistent, giving rise to an average binding affinity (KA) of ~2 × 10
5 M-1. 
 
Figure 3.4 ITC binding data for Gata-1NF titrated into Lmo1-Ldb1LID. Gata-1NF (175 µM) was 
titrated into Lmo1-Ldb1LID at A. 26 µM and B. 19 µM. Experiments were carried out in 20 mM MES, 
100 mM NaCl, 1 mM TCEP, pH 6.5 at 25 °C.  
 
TABLE 3.2 ITC data. The association constant (KA) and the stoichiometric ratio (n) were calculated 
at two different concentrations of Lmo1-Ldb1LID as indicated.  
Parameter 26 µM Lmo1-Ldb1LID 19 µM Lmo1-Ldb1LID 
KA (M-1) 1.2 ± 0.3 × 10
5 3.3 ± 0.9 × 105 
n 0.50 ± 0.06 1.10 ± 0.03  
 
3.3 Can FOG be used to stabilise the Tal/E12/Lmo/Ldb/Gata complex? 
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The Tal/E12/Lmo/Ldb/Gata complex bound to DNA has been purified in the laboratory (Lorna 
Wilkinson-White, unpublished data). Crystals of the complex were produced, however, the 
resolution (8–10 Å) was not sufficient for structure determination.  
As discussed in section 1.2.7, FOG1 is a known interaction partner of Gata-1NF. It has been 
previously demonstrated that Gata-1NF is able to simultaneously interact with FOG1-F1 and 
Lmo2. In overlaying known crystal structures, it appears that FOG1 may have additional 
interactions with the transcriptional complex (Figure 3.1). To that end, we hypothesised that 
addition of FOG1 to the complex may provide additional stability and possibly lead to 
improved crystal packing, therefore improving diffraction. This possibility was investigated by 
assessing the binding of FOG1 to the complex, using size-exclusion chromatography in 
conjunction with multi-angle laser light scattering (SEC-MALLS) to determine whether FOG1 
is able to be co-purified with the other complex components  
  
3.3.1 Expression and purification of constructs 
GFP-USF1 
GFP-USF1 (Section 1.2.7) contains the U-shaped finger 1 (USF1) from Drosophila 
melanogaster, which is tethered to GFP via an 11-residue glycine/serine linker. This construct, 
which was used for the FOG-binding studies described in this thesis, was expressed with an N-
terminal His-gb1 domain tag, where the His-tag is used for purification, and the gb1 domain to 
aid in solubility. The construct was made as part of my Honours Project (V. Caldas, Honours 
Thesis 2015). GFP-USF1 was expressed Rosetta 2 E. coli cells with 1 mM IPTG induction and 
purified as in section 2.3 (Figure 3.5). GFP-USF1 was purified by Ni-NTA chromatography 
(Figure 3.5A), followed by size exclusion chromatography, where it eluted as a single peak. 
Fractions were not of high purity, as some lower molecular weight bands could be observed. It 
is possible that these are degradation products. This achieved a yield of about 20 mL of 57 µM 
from 3 L of expression culture protein, at  >80% purity as judged by SDS-PAGE.   
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Figure 3.5 SDS-PAGE analysis of GFP-USF1 purification. Rosetta™ 2 cells were grown at 37 °C 
before induction with 1 mM IPTG induction at an OD600 nm ~ 0.6 for 22 h at 18 °C. A. GSH-Affinity 
purification. Soluble cell lysate was incubated on Ni-NTA beads for 45 min, and beads washed before 
elution with increasing concentrations of imidazole (20 mM – 400 mM) in 50 mM Tris, 150 mM NaCl, 
0.1% v/v 2-mercaptoethanol, 2 mM PMSF, pH 8. B. Size exclusion chromatography. Eluted protein 
fractions were pooled and concentrated and run on an S75 column in 50 mM Tris, 100 mM NaCl, 1 
mM TCEP, pH 7.  
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Tal1/E47 and Gata-1NC/Ldb1LID-Lmo1LIM2 
The Tal1/E47/Gata-1NC/Ldb1LID-Lmo1LIM2 pentameric complex was generated by co-
expressing each of His-Tal1 and E47, and Gata-1NC and Ldb1LID-Lmo1LIM2, in two separate 
experiments, and the soluble lysates combined prior to cation exchange chromatography 
(Figure 3.6A). Elution fractions that contained the most protein were further purified by Ni-
NTA chromatography using the His tag on His-Tal1 (Figure 3.6B). As expected, four bands 
were observed, Ldb1LID-Lmo1LIM2 (21 kDa), Gata-1NC (13.5 kDa), Tal1 (8.9 kDa), and E47 (7.5 
kDa), at their expected sizes (Figure 3.6B). Although the target proteins are the predominant 
bands, other contaminating proteins were also present. The total amount of protein in the 
pooled and desalted samples was ~16 µM of protein in 30 mL from 6 L of expression culture, 
of which >80% was estimated to be the target pentameric complex.  
 
Figure 3.6 Preparation of the Tal1/E47/ Gata-1NC/Ldb1LID-Lmo1LIM2 pentameric complex 
analysed by SDS-PAGE. Rosetta™ 2 cells were grown at 37 °C before 1 mM IPTG induction at an 
OD600 nm ~ 0.6 for 22 h at 22 °C. A. Cation exchange. Soluble cell lysates were combined and applied 
to sepharose cation exchange resin and eluted with increasing salt (200 mM–1 M NaCl) in 50 mM Tris, 
100 mM NaCl, 0.1% v/v 2-mercaptoethanol, 2 mM PMSF, pH 7. B. Ni-NTA chromatography. Eluted 
protein incubated with Ni-NTA resin and eluted with a step gradient (100–600 mM) of imidazole in 20 
mM Tris, 400 mM NaCl, 0.1% 2-mercaptoethanol, 2 mM PMSF, pH 7.  
 
 
3.3.2 SEC-MALLS 
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SEC-MALLS was used to investigate the association of GFP-USF1 with the pentameric protein 
complex in the presence of DNA. Based on previous experience with the pentameric complex, 
the samples were initially made up at low concentration (~20 µM) and then concentrated prior 
to SEC-MALLS analysis. The concentration of the Tal1/E47/Gata-1NC/Ldb1LID-Lmo1LIM2 
subcomplex was estimated and dsDNA (containing an E-box DNA site and GATA DNA site; 
prepared and supplied by Dr Lorna Wilkinson White) added at a 1.2-fold excess. GFP-USF1 
was also added at a 1.2-fold excess to the subcomplex. Following the addition of DNA, 
significant protein precipitation was observed. Protein was filtered to remove precipitate prior 
to the addition of GFP-USF1, concentration and SEC-MALLS.  
The size exclusion chromatography trace indicated that most of the components eluted as two 
major peaks, with some shoulder peaks and other minor peaks (Figure 3.7A). SDS-PAGE 
analysis indicated that the first peak contained all five protein components, and the second peak 
contained excess GFP-USF1 and small amounts of the other proteins but with little or no Ldb1-
Lmo1. MALLS analysis of this peak (average molecular weight: estimated = 47.5 kDa, 
expected for GFP-USF1 = 42.1 kDa) further suggests the presence of excess GFP-USF1. High 
levels of absorbance at 495 nm further indicate the presence of fluorescent protein in the second 
peak. 
For the main peak, the presence of all five protein components indicates that GFP-USF1 was 
co-eluting with the pentameric complex. MALLS analysis gave a larger estimate than expected 
for a 1:1:1:1:1:1 complex (weight average molecular weight: estimated = 122.6 kDa, expected 
= 90 kDa). This larger estimate is probably due to the presence of high molecular weight 
contaminants that can be seen in both the input and eluted fractions by SDS-PAGE (Figure 
3.7B). Note that the downward slope for the estimated molecular weight (Figure 3.7) indicates 
the presence of multiple species in the peak, and could also indicate some aggregated species. 
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Figure 3.7 Analysis of GFP-USF1 binding to pentameric complex. Tal1/E47/Gata-1NC/Ldb1LID-
Lmo1LIM2 in the presence of DNA (containing E-box and GATA DNA sites) and GFP-USF1 was 
subjected to size-exclusion chromatography using a Sepharose 12 10/300 GL column in 20 mM Tris, 
100 mM NaCl, 1 mM TCEP, pH 7 and analysed by MALLS. BSA was used as a control. A. MALLS 
data. Blue shows differential refractive index. The molecular weight of peak one shown in red, peak 
two in green (kDa). B. SDS-PAGE analysis of MALLS elutions. Peak fractions were collected and 
analysed by SDS-PAGE.  
 
3.4 Ldb1 dimerisation 
The majority of characterisation of the Tal/E12/Lmo/Ldb/Gata complex described thus far has 
used the Ldb1LID domain, which directly contacts the LIM domains of Lmo1 and Lmo2. 
However, Ldb1 also contains an N-terminal self-association domain, which contributes to 
transcription. The dimer formed by this domain facilitates chromatin looping, bringing the 
enhancer and promoter regions into close proximity, thus allowing for transcriptional activation 
at the β-globin locus [23, 28].   
The self-association domain is highly insoluble when expressed in bacteria, making expression 
and purification, and thus further analysis, difficult. This section of work describes efforts to 
express and purify a variety of Ldb self-association domain constructs, with the aim of finding 
one with higher yields of soluble protein for further studies.  
  
 
 
3.4.1 Ldb1 bacterial expression and purification 
Initially, a His-gb1-tagged Ldb1 construct (residues 14–200 from mouse Ldb1) was used. This 
was the same construct that had been crystallised previously in the laboratory (as outlined in 
Section 1.3), following the removal of the His-gb1 tag. Ldb1 was expressed in BL21(DE3) E. 
coli cells with 0.4 mM IPTG induction, and purified by Ni-NTA chromatography (Figure 
3.8A), followed by cleavage of the His-gb1 tag (Figure 3.8B) and anion exchange 
chromatography (Figure 3.8C).  
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Figure 3.8 SDS-PAGE analysis of His-gb1-Ldb1 expression. BL21(DE3) cells were grown at 37 °C 
before 0.4 mM IPTG induction at OD600 nm ~ 0.6 for 22 h at 20 °C. A. Affinity purification. Soluble cell 
lysate was incubated 45 min with Ni-NTA resin at 4 °C and washed in 20 mM Tris, 300 mM NaCl, 20 
mM Imidazole, 0.1% v/v 2-mercaptoethanol, 0.2 mM PMSF, pH 8. B. Cleavage. Protein was cleaved 
overnight with TEV protease (1 µg/µL) at room temperature to remove the His-gb1 tag in 20 mM Tris, 
300 mM NaCl, 20 mM Imidazole, 0.1% v/v 2-mercaptoethanol, 0.2 mM PMSF, pH 8. Protein was 
eluted in four 5 mL fractions. C. Anion exchange chromatography. Cleaved protein was run on a UnoQ1 
column in 50 mM Tris, 1 mM TCEP, pH 8, with an increasing salt gradient (0–1 M NaCl).   
Ldb1 was largely insoluble, as demonstrated by a visible band in the insoluble fraction at the 
expected size (33 kDa). However, a significant amount of protein was still bound to the Ni-
NTA resin following incubation of soluble lysate. Following treatment with TEV protease to 
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remove the His-gb1 tag, it was observed that a large amount of protein remained on the resin, 
including some cleaved and a larger amount of uncleaved target protein. The eluted fractions, 
while containing some cleaved Ldb1, also contained a large number of contaminants (Figure 
3.8B). Following anion exchange chromatography of the eluted protein, many of these 
contaminants were still present. The purity was not considered sufficient for further assays, and 
the protein was not further used. The purification of Ldb1 (14–200) was reattempted; 
unfortunately no improvement of protein purity was observed.  
 
3.4.2 Ldb1 mammalian expression and purification 
As an alternative, expression was trialled in mammalian cells, using Ldb1 (residues 1–200). 
Constructs were used that contained either an N-terminal FLAG-tag or a His-gb1 tag. These 
tags may assist in solubility, and aid in detection via western blot analysis. Proteins were 
expressed in HEK293 EXPI cells for 3 days, and expression assessed via western blot analysis 
using antibodies against FLAG and His-tags as the primary antibodies (Figure 3.9).  
Both FLAG- and His-tagged proteins showed some expression; with equal amounts of each 
sample loaded. The FLAG-tagged protein showed a single robust expression band, with protein 
in both the soluble and insoluble fractions. It should be noted that the detection of the band for 
the soluble fraction appears exceed the limit of detection (as evidenced by the clear strip in the 
middle of the band which is characteristic of the reagent being exhausted in that region). Thus, 
soluble expression may be slightly better than indicated by this western blot (Figure 3.9A). The 
His-gb1-tagged proteins showed approximately equal levels of expression in the total cell and 
soluble samples, with little to no insoluble proteins at the level of detection in the western blot. 
However, there were multiple higher molecular weight bands detected. It should be noted that 
as different antibodies were used for visualisation, quantitative comparisons of expression 
cannot be made for these different preparations. Further work using mammalian expression 
was outside the scope of this thesis. However, assessing the yield following purification would 
be of use to determine whether sufficient quantities can be produced for follow up studies. 
Additionally, antibodies targeting Ldb1 could be utilised to ensure that the observed bands are 
in fact Ldb1, as well as to allow a comparison of expression levels between the two tagged 
proteins.   
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Figure 3.9 Western blot analysis of Ldb1 expression. Constructs were transfected into HEK293 EXPI 
cells and grown for 3 days at 37 °C with shaking. Cells were harvested and washed in PBS followed by 
lysis in 50 mM Tris, 150 mM NaCl, 1% v/v Triton X-100, 1 mM PMSF, 1 x cOmplete, 0.2 mM DTT, 
pH 7.9. A. FLAG-Ldb1. Anti-FLAG antibody used for detection. B. His-gb1-Ldb1. Anti-his antibody 
used for detection. Arrows indicate expected size.  
 
3.4.2 Ldb1-like proteins 
It is possible that another species may have an Ldb1 protein that acts in a similar way to 
mammalian Ldb1. Some of these potentially related proteins do not exhibit high sequence 
homology with Ldb1, but may be evolutionarily related. It is of interest to investigate if these 
proteins can dimerise like Ldb1. The proteins selected for this study were an Ldb1-like protein 
from Caenorhabditis elegans (CeLdb1), and Adn1 from Schizosaccharomyces pombe.  
The protein regions used were selected based on sequence and predicted structural similarity 
to the self-association domain of Ldb1. Of these constructs, a ‘long’ (C. elegans Ldb1 residues 
2–369; Adn1 residues 2–277), termed CeLdb1-L and Adn1-L respectively and ‘short’ version 
(C. elegans Ldb1 residues 76–282; Adn1 residues 2–203), CeLdb1-S and Adn1-S respectively 
were made. The constructs were originally designed by J Matthews and cloned by Jennifer 
Ting (Honours 2016). 
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Using these previously cloned constructs, the self-association of these proteins was assayed 
using yeast two-hybrid analysis (Figure 3.10). However, no interaction could be detected by 
this method.  
 
Figure 3.10 Yeast two-hybrid analysis of self-association of CeLdb1 and Adn1. pGBT9/ pGAD10 
plasmids containing the indicated constructs were transformed and spotted onto SD agar as serial (1:10) 
dilutions (top-to-bottom). Transformants were spotted onto a growth plate (–LW) and onto a selection 
plate (–LWH + 3-AT; 0.5 mM 3-AT and 40 μg/mL X-α-gal).  
It was not clear if the lack of interaction was due to poor levels of soluble expression, so 
bacterial expression trials were carried out for both CeLdb1 (Figure 3.11, Figure 3.13) and 
Adn1 (Figure 3.12, Figure 3.14). Proteins were expressed from pGex vectors giving an N-
terminal GST tag, or from pMal vectors to produce an N-terminal MBP tag. Expression trials 
were carried out as described in section 2.3 in Rosetta 2 and BL21(DE3) E. coli cells with a 
post-induction temperature of 20 °C. Regardless of the species, all of the GST-tagged 
constructs were largely insoluble with little or no protein of the correct molecular weight being 
immobilised on the GSH-resin (Figure 3.11, Figure 3.12). The best of these were the CeLdb1-
S and Adn1-S constructs expressed in Rosetta 2 cells, but the amount of immobilised protein 
was very low and both showed some evidence of breakdown products (Figure 3.11D and 
3.12D). The pMal-constructs showed much higher levels of solubility as evidenced by bands 
of the correct size in the soluble fraction (Figure 3.13, Figure 3.14). In all cases at least some 
protein of the correct size could be immobilised on amylose resin. Additional expression trials 
were carried out with a post-induction temperature of 25 °C, but no changes to solubility were 
observed (data not shown).  
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Figure 3.11 Expression trials of GST labelled CeLdb1. Cells were grown at 37 °C before 0.4 mM 
IPTG induction at OD600 nm ~0.6 for 22 h at 20 °C. Large construct expressed in BL21(DE3) cells (A.) 
and in Rosetta™ 2 cells (B.). Small construct was GST-tagged and expressed in BL21(DE3) cells (C.) 
and in Rosetta™ 2 cells (D.). Arrows indicate expected size. Soluble cell lysate was applied to GSH-
sepharose followed by a wash step. 
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Figure 3.12 Expression trials of GST tagged Adn1. Cells were grown at 37 °C before 0.4 mM IPTG 
induction at OD600 nm ~0.6 for 22 h at 20 °C. Large construct was expressed in BL21(DE3) cells (A.) 
and in Rosetta™ 2 cells (B.). Small construct was expressed in BL21(DE3) cells (C.) and in Rosetta™ 
2 cells (D.). Arrows indicate expected size. Soluble cell lysate was applied to GSH resin followed by a 
wash step. 
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Figure 3.13 Expression trials of MBP labelled CeLdb1. Cells were grown at 37 °C before 0.4 mM 
IPTG induction at OD600 nm ~0.6 for 22 h at 20 °C. Large construct was expressed in BL21(DE3) cells 
(A.) and in Rosetta™ 2 cells (B.). Small construct was expressed in BL21(DE3) cells (C.) and in 
Rosetta™ 2 cells (D.). Arrows indicate expected size. Soluble cell lysate was applied to amylose resin 
followed by a wash step. 
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Figure 3.14 Expression trials of MBP tagged Adn1. Cells were grown at 37 °C before 0.4 mM IPTG 
induction at OD600 nm ~0.6 for 22 h at 20 °C. Large construct was expressed in BL21(DE3) cells (A.) 
and in Rosetta™ 2 cells (B.). Arrows indicate expected size. Soluble cell lysate was applied amylose 
resin followed by a wash step. 
 
The MBP-tagged constructs were investigated further. It should be noted that MBP tags often 
increase protein solubility, but removal of the MBP tag can reverse this effect, resulting in 
precipitation of the target protein. To investigate this, the MBP tags were removed by treatment 
with HRV-3C, targeting a protease site in the linker between the tag and the protein. A time 
course experiment carried out over 45 min showed no cleavage with HRV-3C protease, nor did 
subsequent overnight incubation show any evidence of proteolysis (Figure 3.15). This lack of 
specific proteolysis may be due to the formation of soluble MBP-aggregates (thereby 
preventing access of the protease to the protein), or there may be steric hindrance at the HRV-
3C protease site, caused for example by high levels of structure in the constructs close to the 
linker. Given the high levels of insolubility of the GST-tagged proteins and previous experience 
in the laboratory with highly insoluble protein forming large soluble aggregates when tagged 
with MBP, it was considered that this was also the most likely scenario for these constructs. 
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Figure 3.15 Treatment of MBP tagged proteins with HRV-3C protease. Proteins were incubated 
with HRV-3C protease at 4 °C as indicated. A. CeLdb1-L B. Adn1-S. Arrows indicate uncleaved 
protein.   
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3.5 Conclusions 
The ITC data obtained here indicated that Gata-1NF and Lmo1-Ldb1LID bind with a slightly 
higher affinity to that previously measured for Gata-1NF/Lmo2-Ldb1LID interactions. The 
previous experiments, based on NMR chemical shift perturbation titration data indicated a 
binding affinity of KA = 5 × 10
4 M-1 [75]; compared to KA ~ 2 × 10
5 M-1 for Gata-1NF/ Lmo1-
Ldb1LID. The Gata-1NF/Lmo2-Ldb1LID binding was of low enthalpy such that ITC could not be 
used to determine binding affinity. The slightly stronger binding affinity also possibly indicates 
why Gata-1NF/Lmo1-Ldb1LID had more favourable chemical exchange properties and 
improved NMR spectra relative to Gata-1NF/Lmo2-Ldb1LID.  
As can be seen from the SEC-MALLS data, GFP-USF1 appears to bind to the pentameric 
complex. It is also possible that USF1 simply coelutes with the rest of the complex without 
binding, or that it interacts only with its known binding partner Gata-1. However, the MALLS 
data indicates the formation of a larger complex, and other data from the laboratory indicates 
that USF1 has a significantly longer elution time (L. Wilkinson-White, unpublished data). 
Also, Gata-1 binds USF1 with such low affinity KA ~10
5 M-1 [68], that it if Gata-1NF-USF1 
interactions were solely responsible for USF1 binding, it is unlikely binding would be observed 
in this experiment.  
Under the conditions of the experiment, including the concentrations of the molecules at 
loading and at elution, binding affinities must be >~KA 10
7 M-1 to detect complex formation 
[123, 124]. Thus, the data obtained from the SEC-MALLS data indicates that USF1 is binding 
more than just Gata-1NF, rather it makes additional contacts with other components in the 
complex. In addition to providing a better understanding of how weak interactions can 
contribute to multiprotein transcription factor complex assembly, these interactions could help 
to stabilise the complex and alter crystal packing to aid future structure of a complete 
pentameric complex bound to DNA. It should be noted that the eluted fractions were not of 
high purity, and the experiment should be repeated with proteins of high purity to obtain a more 
accurate molecular weight estimate and for use in future crystallographic studies.  
As FOG1 and USF1 are not identical, further studies should investigate the possibility of 
additional contacts within the complex with murine FOG1 rather than USF1. Murine FOG1 
fingers 1 and 6 bind to Gata-1 and have high sequence homology with USF1 (Figure 3.16A), 
making them good candidates for further investigation. It would also be of interest to test for 
Chapter 3. Investigation of interactions within the Tal1/E2a/Lmo/Ldb/Gata pentameric complex 71 
 
 
 
differences in binding affinities for Gata-1/FOG1 in the presence and absence of components 
of the pentameric complex, using biochemical assays such as ITC or microscale 
thermophoresis. Additionally, mutations disrupting the FOG interaction (Figure 3.16B) with 
the complex could be used to further confirm the presence of this interaction.  
 
Figure 3.16 Alignment of USF1 and murine FOG fingers. A. Sequence alignment of USF1, murine 
FOG1 finger 1 and 6. Bolded residues are involved in the ligation of zinc. Asterisks (*) indicates 
conserved residues while period (.) indicates similar residues. B. Structure of Gata-1/USF1 binding, 
with Gata-1 in blue and USF1 in orange PDB: 1Y0J [68]. Green residues are involved in Gata-1 binding 
[125]. Magenta residues are conserved residues which are not involved in Gata-1 binding. 
Previous experience in the laboratory indicates that the self-association domain of Ldb1 tends 
to be ~30-50% insoluble when expressed in bacteria (P. Stokes, I MacIndoe, Arwen Cross). In 
this thesis, bacterial expression was carried out in BL21(DE3) cells at 20 °C, following the 
same protocol as previously used in our laboratory. This showed significantly more protein in 
the insoluble fraction than in the soluble fraction, whereby protein in the soluble fraction would 
only be visualised following binding to affinity resin. Despite being largely insoluble, a 
significant amount of protein is soluble and can be bound to resin. This protein could not be 
purified to a high enough level of purity for crystallisation, but expression of the protein in 
bacterial and purification for further study is feasible. It should be noted that while the protocol 
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used was the same as that previously used in our laboratory, solubility levels of this protein has 
been found to be highly variable. Expression in mammalian cells may also be feasible, as some 
soluble expression was observed. Future work may involve trialling expression with different 
tags. Additionally, as some soluble expression was observed in mammalian cells, this could be 
carried out on a larger scale and the protein purified to obtain larger amounts of pure protein.   
The Ldb1-like proteins, Ldb1 from C. elegans and Adn1 from S. pombe, showed little to no 
soluble expression from bacteria. Given the poor levels of soluble expression overall, the 
constructs tested do not appear to be ideal for expression and purification in the bacterial 
expression system used. For further study of these Ldb1 homologs and Ldb1-like proteins, 
some optimisation would be required. This could include testing constructs of different lengths, 
alternate expression tags, and/or other expression systems. Soluble expression for either 
protein, in long or short forms, was only observed when constructs were fused to an MBP tag. 
This fusion construct could be further investigated as means for protein expression and 
purification. The protein could be expressed and purified with the MBP tag, however it should 
be noted that MBP-tagged proteins may form soluble aggregates.   
These proteins could be expressed in mammalian cells to determine if expression levels are 
improved in a different expression system. They could also be expressed in yeast cells, which 
may provide a more favourable environment, particularly for Adn1, which is a yeast protein. 
Past studies have found that some proteins cannot be successfully expressed in a bacterial 
system, often due to insolubility [126]. Yeast can provide an improved expression system, as 
it may be able to perform post-translational modifications that may not occur in bacteria[127]. 
The mammalian expression system contains an even wider variety of post translational 
modifications, as well as chaperones and binding partners which may assist in the solubility, 
folding and stability of the expressed protein [128]. If appropriate expression and purification 
protocols can be established, these proteins can be further investigated to find if they self-
associate in the same manner as Ldb1. If they do indeed self-associate, they may also be 
involved in the mediation of chromatin looping. It would be of interest to carry out experiments 
such as 3C to test their ability to mediate chromatin looping, which could assist in 
understanding the evolutionary progression of Ldb1-like proteins. 
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Chapter 4. RLIM/Ldb1 interaction 
 
RLIM targets Ldb1 and associated proteins for degradation, thereby regulating the levels of 
these proteins within the cell [88] (Section 1.4). RLIM contains an N-terminal nuclear 
localisation domain, a RING domain and the so-called basic domain (RLIMBD; residues 326–
403; Figure 4.2). RLIM has been shown to bind Ldb1 in vitro through pull-down assays and 
ubiquitination assays [92]. RLIMBD was reported to be the region that binds Ldb1 based on 
pull-down assays that used bacterially expressed RLIM proteins, [92] (Section 1.4). This 
binding activity by the basic domain has yet to be confirmed by an orthogonal method. 
Additionally, it is not known which portion of Ldb1 is involved in this interaction. In this 
chapter, the binding of Ldb1 to RLIM was investigated using yeast two-hybrid analysis and 
mammalian pull-down assays in an attempt to define the minimal binding domains of each 
protein.  
 
4.1 Previous work 
The work outlined in this section was partially completed during research for my Honours 
thesis project (V Caldas, Honours 2015) and is included to provide context to the experiments 
that were performed for this thesis. 
It was initially proposed that the binding domains of RLIM and SSBP overlap (Section 1.4). 
The SSBP binds the Ldb1/Chip conserved domain (LCCD) but the self-association (SA) 
domain may contribute to binding (A. Cross, P. Stokes, unpublished data). Constructs spanning 
the LCCD and the SA domain were tested for RLIM binding by yeast two-hybrid analysis.  
RLIMBD (residues 306–423) was assayed for binding against previously cloned constructs 
(pGBT9 and pGAD10) of Ldb1 (1–255) and Ldb2 (1–246). However, no evidence of 
interaction between RLIMBD and either Ldb1 (1–255) or Ldb2 (1–246) could be detected. 
RLIMBD was similarly assayed against a larger construct of Ldb1 that also included the LID 
domain (residues 1–330), but no evidence of an interaction was observed (data not shown).  
As there was little evidence of the RLIMBD being responsible for binding to Ldb1 (see above), 
it was decided that we would redefine and confirm the Ldb1 minimal interaction domain. To 
this end, full-length RLIM was PCR-amplified from a cDNA library generated from MEL cells. 
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The PCR-amplified gene was then cloned into pGBT9 and pGAD10 plasmids for yeast two-
hybrid analysis. Full-length RLIM was tested for binding to Ldb1 (residues 1–330) in this assay 
but no evidence of interaction was detected (not shown). 
 
4.2 Yeast two-hybrid analysis 
Yeast two-hybrid assays were used in many parts of this thesis. In these assays one protein, the 
bait, is fused to the GAL4 DNA-binding domain (BD) through insertion of the encoding cDNA 
into a pGBT9 vector. The other protein, the prey, is fused to the GAL4 activation domain (AD) 
through insertion of the encoding cDNA into a pGAD10 vector. The yeast strain used in these 
assays, AH109, is auxotrophic for both tryptophan and leucine, meaning that it requires the 
presence of both tryptophan and leucine in media for growth. The prey plasmid, along with 
encoding the activation domain, also encodes a selection marker, TRP1, a tryptophan 
biosynthesis gene, which allows growth on tryptophan deficient (-W) media. Similarly, the bait 
plasmid encodes a leucine biosynthesis gene, LEU2, allowing growth on leucine deficient (-L) 
media. Yeast cells co-transformed with both plasmids are plated onto media deficient in both 
tryptophan and leucine (-LW; ‘growth plate’); growth will only occur if both the bait and prey 
plasmids have been taken up by the same yeast cells. An interaction between the bait and prey 
results in the transcription of various reporter genes. For the experiments described in this thesis 
the relevant reporter genes were HIS3 and MEL1, which permit yeast co-transformed with an 
interacting bait-prey pair to grow on defined nutrient-deficient media (-Histidine/-H for HIS3, 
which encodes an enzyme on the biosynthetic pathway for histidine synthesis) or to produce 
blue colour from the addition of α-X-gal (MEL1, which encodes α-galacatosidase) (Figure 4.1). 
If there is no interaction between the bait and prey, or either of these proteins are not present 
(as is the case for some negative control experiments), the yeast will not grow, or produce 
colour. Various controls, both negative (empty vector) and positive (e.g., between Ldb1LID and 
Lmo4), were carried out. Negative controls assist in the detection of false positives as yeast 
two-hybrid assays may show background activity, and positive controls provide an indication 
that the methodology is working as expected. To increase the stringency of this assay, thereby 
decreasing the occurrence of false positives, 3-amino-1, 2, 4-triazole (3-AT) was used. 3-AT 
acts as a competitive inhibitor of the enzyme encoded by HIS3. For yeast to successfully grow, 
sufficient amounts of this enzyme must be expressed to overcome the inhibition of 3-AT, 
indicating a stronger interaction than one which cannot grow in the presence of 3-AT. It should 
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be noted that due to the variability of yeast-two hybrid, there is no well-defined range of 
association constants that can be detected by this assay. Variability arises from a variety of 
factors, such as expression levels, compartmentalisation and stability in yeast of the proteins 
being tested [129]. That said, the use of different selection conditions such +/- 3-AT can still 
give an indication of protein interaction strength for similar protein classes.  
 
Figure 4.1. Schematic of yeast two-hybrid analysis. When bait and prey interact the transcriptional 
activity of GAL4 is reconstituted allowing for activation (transcription) of reporter genes. 
 
4.3 Generation of additional Ldb constructs 
The work discussed in the following sections were completed as a part of this thesis. The Ldb1 
construct used previously, while containing both the self-association domain and the LID, was 
missing 45 residues from the C-terminus. It is possible that these residues are required for 
binding to RLIM. To investigate this possibility, full-length Ldb1 was generated. This was 
achieved as described above for RLIM. RNA was extracted from MEL cells and the cDNA for 
Ldb1 was generated and cloned into yeast two-hybrid vectors pGBT9 and pGAD10. Attempts 
were made to similarly generate full-length Ldb2 for comparison; however, attempts to clone 
the cDNA for this gene were not successful. The lack of success may be due to the lower 
expression levels of Ldb2 in MEL cells. The mouse genome expression database [130] was 
used to identify tissues in which Ldb2 is highly expressed. From this database, it was 
determined that murine Ldb2 is mainly expressed in the lung, brain, kidney and hippocampus. 
cDNA libraries were generated from purified RNA from mouse kidney and mouse cerebellum 
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(the RNA samples were provided by David So Ri Jung and Taylor Syme at the University of 
Sydney). However, the Ldb2 gene could not be PCR-amplified from the cDNA libraries. 
Finally, a synthetic gene fragment (IDT g-block) for this gene was purchased and cloned into 
yeast two-hybrid vectors. 
Constructs were also generated for mammalian expression. For these constructs, full-length 
Ldb1 and RLIM were cloned into pcDNA3.1 vectors containing either a N-terminal FLAG- or 
a HA-tag, using Gibson Assembly (Section 2.2.3). Truncation mutation constructs of RLIM 
and Ldb1 were generated using the same method. Two truncation mutants of RLIM were 
designed and generated (Figure 4.2A), RLIMBD (residues 306–426) and RLIMRING (residues 
426–600). Two truncation mutants of Ldb1 were designed (Figure 4.2B), Ldb1SA/LCCD 
(residues 1–259) and Ldb1LID (residues 259–375). However, only Ldb1LID was successfully 
generated.  
 
Figure 4.2 Schematic of RLIM and Ldb1 constructs generated. A. RLIM. RLIM contains a nuclear 
localisation signal region (NLS), a basic domain (BD) and a RING (Really Interesting New Gene) 
domain. RLIMBD is made up of residues 306–426, and RLIMRING comprises residues 426–600. B. Ldb1. 
Chapter 4. RLIM/Ldb1 interactions  77 
 
 
 
Ldb1 contains a self-association domain (SA), a Ldb1/CHIP conserved domain (LCCD) and a LIM 
interacting domain (LID). Ldb1SA/LCCD is made up of residues 1–259, and Ldb1LID is made up of residues 
259–600. C. Ldb2. Ldb2 contains a self-association domain (SA), a Ldb/CHIP conserved domain 
(LCCD) and a LIM interacting domain). Red shows regions predicted to be disordered. Disorder 
predictions generated by DISOPRED [131].  
 
4.4 Yeast two-hybrid analysis 
Full length Ldb1 and Ldb2 cloned into the yeast vectors pGBT9 or pGAD10 were tested for 
binding against full-length RLIM on histidine-deficient media containing X-α-gal and 0.5 mM 
3-AT (Figure 4.3). Successful co-transformation of all sets of plasmids were demonstrated by 
growth on –LW media. Ldb1LID/Lmo4 co-transformants, used as a positive control, gave rise 
to blue colonies indicating the presence of an interaction as expected (Figure 4.3A, lane 1). 
However, no evidence of interaction between RLIM and either Ldb1 or Ldb2 could be detected 
(Figure 4.3A and B, lane 2). As Ldb1 and Ldb2 contain regions that are predicted to be 
disordered (Figure 4.2B, C), additional positive controls were used to ensure the proteins were 
not degraded during yeast experiments. Ldb1 and Ldb2 were tested for binding against 
constructs containing their respective self-association domains, Ldb1 (residues 1–255) and 
Ldb2 (residues 1–246), to ensure that the self-association domain was intact (Figure 4.3A, lane 
8; 4.3B lane 5). They were also tested for binding against Lmo4 to check that the LID domain 
was intact (Figure 4.3A, lane 10 and 11; 4.3B lane 7). Growth on –LW plates was observed for 
all transformants indicating the successful co-transformation of both plasmids. Negative 
controls, whereby either pGBT9 or pGAD10 were empty were also carried out to test for 
autoactivation, which causes background growth. Autoactivation only occurred when Ldb1 
was in pGBT9 (Figure 4.3A, lane 6). Ldb1 showed evidence of positive interactions for both 
sets of controls, indicating that both the N- and C-termini (at least until the end of the LID) 
were functional and available for binding in yeast two-hybrid assays, while Ldb2 showed a 
positive interaction only with Lmo4 (Figure 4.3B), indicating that the C-terminus was intact. 
As the N-terminus of Ldb2 is fused to the C-terminus of the GAL4-activation domain in the 
pGAD10 constructs, these data suggest that the Ldb2 construct is in intact at least until the end 
of the LID. Hence, it is not clear why there was no detectable association of Ldb2 (1–246) to 
full length Ldb2. Although it used constructs with a slightly shortened N-termini (starting at 
residues 11, 16 or 21) (Arwen Cross, PhD Thesis 2010), so the lack of evidence for an 
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interaction could be due to the Ldb2 (1–246) construct not expressing as well as the longer 
constructs.  
-
 
Figure 4.3 Yeast two-hybrid analysis of Ldb1/Ldb2 and RLIM interactions. A. Ldb1 and RLIM 
interactions. B. Ldb2 and RLIM interactions. pGBT9/pGAD10 plasmids containing the indicated 
constructs were transformed and spotted onto SD agar as serial (1:10) dilutions (top-to-bottom). Co-
transformants were spotted onto a growth plate (–LW; not shown) and onto a selection plate (–LWH + 
0.5 mM 3-AT + 40 μg/mL X-α-gal). See text for details of positive controls. The image was edited to 
show only the relevant constructs.  
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No interaction was observed between RLIM and either Ldb1 or Ldb2 in this assay. Given that 
Ldb2 did not exhibit the expected positive interaction with its self-association domain, it was 
not further investigated in this study.  
4.5 Mammalian expression 
The null interaction between RLIM and Ldb1 in the yeast two-hybrid assay could arise if it is 
not optimal to express the RLIM mammalian protein in a yeast system. Hence, a different 
expression and assay system was used. For this study, only Ldb1 was tested. The constructs 
were generated in pcDNA3.1 vectors with a N-terminal FLAG- or HA-tag and co-expressed in 
HEK293 cells using transient expression (Section 2.4.1). First the expression of full-length 
constructs was confirmed (data not shown) and then FLAG pull-downs were carried out. In 
these experiments the FLAG-tagged protein acts as the bait, and the HA-tagged protein as the 
prey. Cells were lysed and the soluble lysate (the input lanes in Figure 4.4) was incubated with 
anti-FLAG resin to immobilise the bait protein. This was followed by a wash step and elution 
with 3× FLAG-peptide. The input and eluate samples were visualised using SDS-PAGE 
followed by western blot with anti-FLAG and anti-HA antibodies. These experiments were 
conducted with RLIM and Ldb1 in both orientations of bait and prey. The interaction between 
full-length RLIM and Ldb1 was observed for both experiments, as shown by the prey protein 
being pulled-down by the bait protein (Figure 4.4).  
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Figure 4.4 Western blot analysis of the interaction of RLIM and Ldb1. Constructs were transfected 
into HEK293 EXPI cells and grown for 3 days at 37 °C with shaking. Cells were harvested, washed and 
lysed. The soluble lysate was incubated with anti-FLAG resin prior to washing and elution with 3× 
FLAG peptide. Input and elution fractions were analysed via western blot, using simultaneous blotting 
with anti-FLAG and anti-HA antibodies. Western C standard did not image clearly. An interaction 
between full-length RLIM and Ldb1 could be observed. 
Following the confirmation of this interaction between the full-length proteins, the truncation 
mutant pcDNA3.1-based constructs were generated (Figure 4.2) and co-expressed in HEK293 
cells, with the intent of identifying the minimal binding domains of Ldb1 and RLIM. However, 
analysis of expression levels showed that the RLIMBD construct showed no detectable 
expression in both the FLAG- and HA-tagged versions (Figure 4.5). While some expression of 
Ldb1LID and RLIMRING could be observed, these expression levels were very low (Figure 4.5). 
Due to the low expression levels of the truncation mutants, further analysis of these constructs 
was not carried out.  
 
Figure 4.5 Western blot analysis of expression levels of RLIM and Ldb1 constructs. Constructs 
were transfected into HEK293 EXPI cells and grown for 3 days at 37 °C with shaking. Cells were 
harvested and total cell lysate subjected to western blot analysis visualised using simultaneous blotting 
with anti-FLAG and anti-HA antibodies.  
 
4.6 Conclusions 
Chapter 4. RLIM/Ldb1 interactions  81 
 
 
 
This study confirmed that an interaction between RLIM and Ldb1 occurs in mammalian cells, 
as evidenced by pull-down experiments. That the same interaction could not be observed in 
yeast two-hybrid analysis suggests that the yeast two-hybrid result is a false negative result. 
There may be several reasons for this. The first is that RLIM is degraded or poorly expressed 
in yeast cells. The integrity of Ldb1 was assessed by testing interactions with the Ldb1SA self-
association domain and with Lmo4; these interactions test the N-terminal and C-terminal 
halves of Ldb1, respectively. However, such similar tests for RLIM were not available. 
Secondly, RLIM is predicted to be highly disordered (Figure 4.6); only the RING domain has 
a strongly-predicted folded domain. As discussed in Section 1.5.2, disordered proteins may be 
difficult to express as they are prone to aggregation and degradation. This disorder may lead to 
degradation of the protein, meaning that the assays could be compromised by truncated or 
degraded RLIM in yeast cells. Previous studies have investigated the incompatibility of various 
proteins with yeast two-hybrid analysis [132]. Post-translational modifications that are required 
for folding and/or interactions may not be correctly added to the expressed mammalian proteins 
in yeast cells [132, 133]. This may be of particular relevance for RLIM, as intrinsically 
disordered proteins or regions are often the site of post-translational modifications [95]. Lastly, 
the fused Gal4 effector proteins may prevent the interaction by steric hindrance[132, 133].  
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Figure 4.6 Disorder prediction generated using DISOPRED [131] for full-length human RLIM. 
Disorder prediction is represented in blue, where the protein is likely to be disordered in regions where 
confidence score is over 0.5. RLIM contains a nuclear localisation domain (NLS), a basic domain (BD), 
and a RING (Really Interesting New Gene) domain. 
Despite the clear interaction observed with the full-length proteins when expressed in 
mammalian cells, this was not observed for the truncation mutants as they showed little to no 
expression of the proteins. This observation may also be attributed to the disordered nature of 
RLIM. Some work has been done to investigate the stabilisation of such proteins, as described 
in chapter 5.  
If RLIM can be stabilised, the interaction can be further investigated to define the minimal 
binding domains of both RLIM and Ldb1. Following this, site-directed mutagenesis could be 
utilised to find the residues involved in the interaction to aid in understanding the mechanisms 
by which RLIM regulates Ldb1 levels within the cell. It may also be of interest to investigate 
if RLIM and SSBP do compete for binding to Ldb1. This process could control the levels of 
Ldb1 and associated proteins in the cell, including the transcriptional complex discussed in 
chapter 3. The up- or down-regulation of this pentameric complex would in turn up- or down-
regulate chromatin looping, and thus gene activation at the β-globin locus and other sites.     
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Chapter 5. Intrinsically disordered proteins 
 
Intrinsically disordered proteins (IDPs) or regions (IDRs) play a variety of key biological roles 
through mechanisms such as protein-protein interactions that can be regulated through post-
translational modifications. Despite their biological importance, they can often be difficult to 
study as they may be prone to aggregation and degradation (Section 1.5)  
Some evidence from our laboratory has suggested that these proteins may be stabilised via the 
fusion of an additional domain. As discussed in Section 1.5.6 the LID domain of Deaf1 and 
CtIP, which is disordered, has been shown to be stabilised using dimerisation domains to enable 
its interaction with Lmo4 to be detected in yeast two-hybrid assays. 
This approach was further investigated in this study, in which various dimerisation domains 
were selected for tethering onto disordered domains. These constructs were assessed for 
changes in stability via yeast two-hybrid analysis, i.e., the ability of yeast to grow under 
different selection conditions, as described in Section 4.2 to determine if this approach may be 
of use of other disordered proteins or regions.  
 
5.1 Selection of dimerisation domains 
Deaf1LID was selected to investigate the stabilisation of disordered proteins and regions, as it 
was previously shown to be stabilised by dimerisation domains (Section 1.5.6). All interactions 
were assayed for binding to Lmo4, a known binding partner of Deaf1LID. Additionally, Ldb1LID 
was selected as a positive control as the LID domain of Ldb1 is also disordered but when tested 
for binding against Lmo4 in yeast two-hybrid assays results in a strong positive signal. 
Three dimerisation domains were selected for this study.  These domains have been previously 
investigated in our laboratory, and have been shown to express in yeast, bacterial and 
mammalian expression systems.  
These dimerisation domains were (i) the N-terminal coiled-coil domain from CtIP; (ii) the 
leucine zipper from GCN4 and; (iii) GST. The N-terminal coiled-coil of CtIP has previously 
been shown to stabilise CtIPLID [134] and the leucine zipper of GCN4 could replace the coiled-
coil of Deaf1LID, allowing an interaction to be detected (Section 1.5.6).  The domain from CtIP 
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is 106 residues in length and the leucine zipper of GCN4 is 32 residues long. GST is a larger 
220-residue globular protein that has been extensively studied, used for protein expression and 
purification, and is stable and soluble.  
  
5.2 Cloning of constructs 
5.2.1 Design of constructs 
Constructs were designed to have the dimerisation domain tethered to either the N- or C-
terminus of Deaf1LID to determine if the orientation of the construct alters the stability of the 
protein. Additional constructs with two dimerisation domains were designed, with one on either 
side of Deaf1LID (Figure 5.1). All constructs were also designed with Ldb1LID in place of 
Deaf1LID. Constructs of Deaf1LID-only, Ldb1LID-only and dimerisation-only domains were 
made as controls for background growth in the yeast two-hybrid assays caused by 
autoactivation or similar artefacts. The constructs were designed with linkers between the LID 
and the dimerisation domains to ensure that dimerisation is not sterically hindered. These 
glycine/serine-rich linkers were intended to be flexible and contained specified protease 
cleavage sites, an HRV-3C protease site and/or a TEV protease site (Figure 5.1), for use in 
experiments in which the constructs could be expressed and purified, and whether removal of 
the dimerisation tag or tags affects stability of the constructs.   
 
Figure 5.1 Dimerisation domain construct design. Deaf1LID constructs were designed with 
dimerisation domains (DD) on the N and/or C termini. Linkers were glycine-serine-rich linkers with 
HRV-3C(3C) or TEV protease sites.   
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The constructs were also designed to contain unique restriction sites between the different 
domains that could be utilised for the generation of constructs. This approach allows a single 
domain to be excised and be replaced with a different domain at the DNA level. This design 
would be of particular use for removing Deaf1LID and replacing it with a different disordered 
domain of interest.  
For the remainder of this chapter, the coiled-coil domain of CtIP will be referred to as CtIP, 
and the leucine zipper of GCN4 as GCN4.  
 
5.2.2 Cloning trouble shooting 
Constructs were initially cloned via Gibson Assembly methods (Section 2.2.3). Each fragment 
was PCR-amplified with substantial overlap with other fragments or the pGAD10 plasmid. 
Fragments required for each construct were combined for Gibson Assembly cloning, prior to 
bacterial transformation. This approach had a low success rate; only control constructs that did 
not contain the glycine-serine-rich linker were successfully generated.  
As Gibson Assembly can be problematic for constructs that contain repeated sequences or 
linkers, and decreases in efficiency when more fragments are combined [135], an alternate 
approach was used. In this new approach, DNA fragments were PCR-amplified, as previously, 
and joined by overlap extension PCR, to generate single fragment inserts that would encode 
the tethered constructs. This approach was used successfully to generate PCR products of the 
expected size for almost all constructs (Figure 5.2).   
 
 
Chapter 5. Intrinsically Disordered Proteins  86 
 
 
 
 
Figure 5.2 Single fragment inserts following overlap extension PCR. Fragments corresponding to 
multi-domain inserts were generated using pfu polymerase, followed by overlap extension PCR, to fuse 
fragments, and amplify the full-length fragments. The PCR products were run on a 1% w/v agarose gel 
stained with HydraGreen. The most intense band in each lane corresponds to the expected size of the 
PCR product. 
Following the generation of these fragments, attempts were made to clone these fragments into 
pGAD10 and pGBT9 using restriction enzyme digestion and directional DNA ligation. This 
approach had a very low success rate; most ligation plates contained no colonies. From the 
plates that did have a few colonies, screening by diagnostic restriction enzyme digestion of the 
purified plasmids indicated that most of the plasmids did not contain an insert. The approach 
was successful only for those constructs that contained 2 domains (a LID and a dimerisation 
domain; GCN4-Deaf1LID, GST-Deaf1LID, CtIP-Deaf1LID, GST-Ldb1LID; Table 5.1). Although 
constructs in which the LID was flanked by a dimerisation domain at each terminus were 
generated by overlap extension PCR, they were not successfully ligated into the target plasmid 
despite several attempts.  
To circumvent the low success rates of cloning for these multidomain constructs, a third 
method was utilised. TOPO™ cloning is a one-step cloning procedure using topoisomerase I 
to facilitate the insertion of a blunt-ended PCR product into the supplied pCR-Blunt II-TOPO™ 
vector. This approach yielded a high number of clones. During the screening step using 
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diagnostic digests, all tested colonies were found to have an insert of the correct size (Figure 
5.3), and were confirmed to be the correct insert by DNA sequencing.  
 
Figure 5.3 Diagnostic restriction digests of constructs. Constructs were generated using TOPO™ 
cloning and restriction digested with BamHI and EcoRI. Products were run on a 1% (w/v) agarose gel 
stained with HydraGreen. 
The next step of cloning procedure was to move the constructs into a plasmid vector compatible 
with yeast two-hybrid analysis. Thus, restriction digest reactions (Section 2.2.7) using a 1:3 
molar ratio of vector to insert were used to clone the insert into pGAD10 and pGBT9 vectors. 
Transformation following the ligation step from these experiments did not yield clones. 
Multiple approaches were used to try and resolve this problem. Different molar ratios of vector 
to insert (1:1, 1:2, and 1:6) were trialled but were not successful. Changes to the transformation 
protocol were also tested. In the standard protocol cells were heat shocked by taking the 
cells/ligation reaction mixture from 4 ºC to 37 ºC, and allowing the cells to incubate at this 
temperature before adding LB and allowing the cell to recover for 2 h at 37 °C. In the altered 
protocol cells were heat shocked at 42 °C for set times between 30–90 s, and SOC media was 
used for the recovery step to provide the cells with a more nutrient rich environment. The 
recovery time was also altered, from 30 min to 2 h. Most of these attempts produced no colonies 
following transformation, with the only constructs successfully cloned from the TOPO™ 
vector to pGBT9 being GCN4-Deaf1LID-CtIP and GCN4-Deaf1LID-GST (Table 5.1).  
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Chemical transformation protocols were used for transformation. Initially, the transformation 
protocol used KCM buffer (Section 2.1.3). Subsequently, a TFBI buffer (Section 2.1.3) was 
used, which increased transformation efficiency, shown via test transformations, whereby 10 
ng of plasmid was transformed and found to have significantly more colonies that that from 
KCM (KCM yielded 2 × 107 cfu/µg DNA; TFBI yielded 2.5 × 108 cfu/ug DNA). This led to 
some colonies being produced by ligation of overlap extension products, but only some 
contained the correct sequence (GST-Deaf1LID-CtIP, GST-Deaf1LID-GCN4, CtIP-Deaf1LID-
GCN4, Deaf1LID-GST and Deaf1LID-CtIP; Table 5.1). In an attempt to improve the efficiency 
of ligation, T4 ligase was used in place of Quick-Stick ligase, but there was no further change 
in the yield of transformation colonies.  
While some success had occurred in the generation of these constructs, most constructs had not 
been cloned. Further attempts were made using overlap extension PCR followed by ligation. 
Following these attempts, diagnostic restriction enzyme digestion using BamHI/EcoRI 
indicated  that all plasmids tested contained an insert of approximately 600 bp regardless of the 
expected size (Figure 5.4).  
 
 
 
 
Chapter 5. Intrinsically Disordered Proteins  89 
 
 
 
 
Figure 5.4 Screening of pGAD10 and pGBT9 plasmids containing dimerisation domain 
constructs. Constructs were PCR-amplified, followed by BamHI/EcoRI digestion for 2 h at 37 °C, and 
ligated and transformed into pGAD10 and pGBT9. DNA was amplified and extracted from colonies 
digested with BamHI/EcoRI for 2 h at 37 °C. Digested plasmids were run on a 1% w/v agarose gel 
stained with HydraGreen. 
Several attempts to clone the remaining constructs were made using both ligation following 
PCR amplification and Gibson Assembly protocols, but the 600 bp insert persisted. The source 
of this insert could not be identified, hindering the generation of the remaining constructs. At 
this stage 25 constructs had been cloned (Table 5.1). The decision was made to focus on other 
experimental techniques, while the 33 remaining constructs in table 5.1 were cloned by Dr Neil 
Robertson. Dr Robertson also found these constructs difficult to clone, and three originally 
planned constructs were omitted from the study because they could not be cloned despite 
multiple attempts. 
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TABLE 5.1 Cloning of constructs. Constructs cloned in this project shown in yellow. 
Constructs cloned by Dr Neil Robertson shown in red. White constructs indicate those that 
were not cloned. The cloning method successfully used is indicated.  
  pGAD10 pGBT9 
Ldb1LID     
DEAF1LID  Gibson cloning  Gibson cloning 
GST  Gibson cloning  Gibson cloning 
GCN4  Gibson cloning  Gibson cloning 
CtIP  Gibson cloning  Gibson cloning 
GST-Ldb1LID  Overlap extension-PCR   
GCN4-Ldb1LID     
CtIP-Ldb1LID     
GST-DEAF1LID  Overlap extension-PCR  Overlap extension-PCR 
GCN4-DEAF1LID  Overlap extension-PCR  Overlap extension-PCR 
CtIP-DEAF1LID  Overlap extension-PCR  Overlap extension-PCR 
GST-Ldb1LID-GCN4     
GST-DEAF1LID-GCN4  Overlap extension-PCR  Overlap extension-PCR 
GST-Ldb1LID-CtIP     
GST-DEAF1LID-CtIP  Overlap extension-PCR  Overlap extension-PCR 
GCN4-Ldb1LID-GST     
GCN4-DEAF1LID-GST    TOPO cloning 
GCN4-Ldb1LID-CtIP     
GCN4-DEAF1LID-CtIP    TOPO cloning 
CtIP-Ldb1LID-GCN4     
CtIP-DEAF1LID-GCN4    Overlap extension-PCR 
CtIP-Ldb1LID-GST     
CtIP-DEAF1LID-GST     
Ldb1LID-GST     
Ldb1LID-GCN4     
Ldb1LID-CtIP     
DEAF1LID-GST  Overlap extension-PCR  Overlap extension-PCR 
DEAF1LID-GCN4     
DEAF1LID-CtIP  Overlap extension-PCR   
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5.3 Yeast two-hybrid analysis 
All constructs in Table 5.1 were assayed for binding to Lmo4 in yeast two-hybrid assays. As 
expected, Deaf1LID showed no evidence of an interaction with Lmo4, while Ldb1LID showed 
strong evidence of binding (robust yeast growth under a variety of selection conditions) in this 
assay (Figure 5.5). When tethered complexes containing Ldb1LID were assayed for binding to 
Lmo4, no change occurred in levels of yeast growth (Figure 5.6). The dimerisation domains 
alone were assayed for background binding interactions with Lmo4, but no interaction was 
observed (Figure 5.5). Each construct was also assayed for autoactivation, with no such activity 
being observed. When dimerisation domains were tethered onto Deaf1LID, some interactions 
were observed depending on the domain used and the orientation of bait and prey (Figure 5.7).  
 
Figure 5.5 Yeast two-hybrid analysis of control constructs binding to Lmo4. Deaf1LID, Ldb1LID, 
GCN4, CtIP and GST constructs were assayed for binding to Lmo4. Constructs were in either pGBT9 
or pGAD10, as indicated, with Lmo4 in the other. pGBT9/pGAD10 plasmids containing the indicated 
constructs were transformed and spotted onto SD agar as serial (1:10) dilutions (left-to-right). Co-
transformants were spotted onto a growth plate (–LW; not shown) and onto a selection plate (–LWH + 
0.5 mM 3-AT + 40 μg/mL X-α-gal). The interaction column indicates the presence (+) or absence (-) 
of an interaction with Lmo4 (observed via yeast growth). 
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Figure 5.6 Yeast two-hybrid analysis of Ldb1LID constructs binding to Lmo4. Ldb1LID was fused to 
GST, the leucine zipper of GCN4, or the coiled-coil of CtIP. All constructs were assayed for binding to 
Lmo4. Ldb1LID constructs were in either pGBT9 or pGAD10, as indicated, with Lmo4 in the other. 
pGBT9/pGAD10 plasmids containing the indicated constructs were transformed and spotted onto SD 
agar as serial (1:10) dilutions (left-to-right). Co-transformants were spotted onto a growth plate (–LW; 
not shown) and onto a selection plate (–LWH + 0.5 mM 3-AT + 40 μg/mL X-α-gal). GST-Ldb1LID in 
pGBT9 and GST-Ldb1LID-CtIP in pGAD10 were not tested as they could not be cloned. The interaction 
column indicates the presence (+) or absence (-) of an interaction with Lmo4 (observed via yeast 
growth). 
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Figure 5.7 Yeast two-hybrid analysis of Deaf1LID constructs binding to Lmo4. Deaf1LID was fused 
to GST, the coiled-coil of GCN4, or the leucine zipper of CtIP. All constructs were assayed for binding 
to Lmo4. Constructs were in either pGBT9 or pGAD10, as indicated, with Lmo4 in the other. 
pGBT9/pGAD10 plasmids containing the indicated constructs were transformed and spotted onto SD 
agar as serial (1:10) dilutions (left-to-right). Co-transformants were spotted onto a growth plate (–LW; 
not shown) and onto a selection plate (–LWH + 0.5 mM 3-AT + 40 μg/mL X-α-gal). CtIP-Deaf1LID-
GST in pGBT9 could not be cloned. The interaction column indicates the presence (+) or absence (-) 
of an interaction with Lmo4 (observed via yeast growth). 
When dimerisation domains were singly tethered onto Deaf1LID, some interactions were 
observed depending on the domain used and the orientation of bait and prey (Figure 5.7). 
Generally, a stronger interaction, as assessed by higher levels of yeast growth, was observed 
when Deaf1LID was in pGAD10, and Lmo4 in pGBT9, as shown by increased growth and blue 
pigment (Figure 5.7, pGAD10 column). The tethering of GST showed little to no effect on 
levels of yeast growth. Evidence of an interaction was observed only when GST was tethered 
to the N-terminus of Deaf1LID in pGAD10 (GST-Deaf1LID), and when part of a double tethered 
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construct the addition of GST showed no evidence of an increase in binding compared to the 
other single tethered domain only in that position.  
Tethering of the leucine zipper of GCN4 or the coiled-coil of CtIP to Deaf1LID allowed 
detection of an interaction. Both coiled-coil domains appeared to stabilise Deaf1LID to a similar 
extent when the coiled-coils were tethered to the N-terminus or the C-terminus. It was noted 
that a stronger interaction was observed when the Deaf1LID construct was in pGAD10, rather 
than pGBT9. In most cases, there was not an obvious increase in yeast growth going from the 
single-tethered to the double tethered constructs. Some of the double tethered constructs (GST-
Deaf1LID-CtIP and GCN4-Deaf1LID-GST) only showed an interaction when in pGAD10. The 
most robust yeast growth was observed with both GCN4 and CtIP fused to Deaf1LID; for these 
constructs, robust yeast growth, at a higher level than the singly bound versions, was observed 
in both orientations of bait and prey 
 
5.4 Tethering of dimerisation domains to RLIM  
It was decided to use the dimerisation stabilisation assay to test the binding of RLIM to Ldb1 
in yeast two-hybrid assays. As discussed in Chapter 4, no evidence for an interaction could be 
observed between RLIMBD and full length Ldb1 in yeast two-hybrid, despite the interaction 
being previously reported in GST pull-down assays [89], and the observation being observed 
in mammalian pull-down assays (Section 4.5).  
Based on the data for Deaf1LID above, three dimerisation stabilisation constructs were selected 
for testing: GCN4-RLIMBD, CtIP-RLIMBD and GCN4-RLIMBD-CtIP. These represents the 
most stabilising single and double tethered constructs identified above. 
RLIMBD was PCR-amplified with overhangs designed to complement either the linker region 
of the tethered constructs, or the pGAD10 vector, and digested with Sma I and Kpn I. Deaf1LID 
was excised from the corresponding tethered construct plasmids via restriction digest with the 
same enzymes. The resulting linearised plasmid, containing the vector backbone and the 
dimerisation domain(s), was combined with the RLIMBD PCR fragment, and treated with 
QuickStick ligase. Although this experiment was repeated several times, no colonies with the 
correct insert were obtained. Instead, these constructs were generated by overlap extension, 
followed by ligation. GCN4-RLIMBD-CtIP was successfully cloned into both pGBT9 and 
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pGAD10. CtIP-RLIMBD could only be cloned into pGAD10, and GCN4-RLIMBD could not be 
cloned within the timeframe of this project.  
Each of these constructs were assayed for binding against full-length Ldb1 (Figure 5.8). No 
interaction between RLIMBD alone and Ldb1 could be detected, as previously observed (Figure 
4.2). GCN4 and CtIP alone, used as controls, showed no background interaction with RLIMBD 
or Ldb1 (data not shown).  
 
Figure 5.8 Yeast two-hybrid analysis of RLIMBD constructs binding to Ldb1. A. RLIMBD was 
assayed for binding to full-length Ldb1. B. RLIMBD was fused to the leucine zipper of GCN4 or the 
coiled-coil domain of CtIP. All constructs were assayed for binding to Ldb1. RLIMBD constructs were 
in either pGBT9 or pGAD10, as indicated, with Lmo4 in the other plasmid. C. Ldb1 was assessed for 
auto-activation, whereby Ldb1 was assayed for binding to an empty vector. pGBT9/pGAD10 plasmids 
containing the indicated constructs were transformed and spotted onto SD agar as serial (1:10) dilutions 
(left-to-right). Transformants were spotted onto a growth plate (–LW; not shown) and onto a selection 
plate (–LWH + 0.5 mM 3-AT + 40 μg/mL X-α-gal). Interaction column indicates the presence (+) or 
absence (-) of an interaction with Lmo4 (observed via yeast growth). 
The tethering of GCN4 and/or CtIP to RLIMBD did not result in the detection of an interaction 
with Ldb1 (Figure 5.8A–B). A small amount of growth was observed in some assays, but this 
 
Chapter 5. Intrinsically Disordered Proteins  96 
 
 
 
was shown to be Ldb1 autoactivation, which occurs when Ldb1 is present in pGBT9 (Figure 
5.8C). Due to time constraints, further testing of these constructs was not carried out.  
5.5 Conclusions 
Several problems arose in the process of cloning of the constructs designed for this study. Most 
constructs required several attempts to be cloned, with a few not being successfully cloned in 
the timeframe of this project. It was hypothesised that this may be a result of the linkers used 
between domains. The repeating sequences may have increased the difficulty in combining 
fragments into the required vector. Generally, the PCR product could be successfully amplified, 
despite the repeating sequences. The linker was predominantly composed of the HRV-3C 
protease site or TEV protease site with a 2-residue glycine/serine linker on each side. No 
significant difference was noted in the efficiency of cloning between the two linker types. 
Problems arose largely in the ligation step, but the cause of this was not determined. 
GST was found to have less stabilisation ability than the other dimerisation domains tested. 
This may be due to its size, as it is significantly larger (26 kDa) than the portions used of CtIP 
(13 kDa) or GCN4 (4 kDa). Only a small portion of GST forms the dimer interface [136]. The 
N-terminus is proximal to the dimerisation interface, while the C-terminus is located further 
away (Figure 5.9). The relative positions of these termini mean that dimerization of GST itself 
could prevent the interaction domains from being able to make sufficiently close contact to 
bind, or inclusion of GST in these vectors could sterically inhibit the Gal4 domains. This is 
unlikely, as the Ldb1/Lmo4 interaction was not impeded by the presence of GST (Figure 5.6) 
and constructs used in the pGEX-2T vector, which contains a GST tag (tethered via the C-
terminus) to aid in expression and solubility contain a shorter linker between the protein of 
interest and the GST tag than the linker used in this project. 
Note that the structure depicted in Figure 5.9 shows that of GST from Rattus norvegicus, as 
more studies on its dimerisation have been carried out, while the GST used for this project was 
from Schistosoma japonicum. They have high sequence similarity and an overlay of structures 
shows high structural similarity. GST family proteins have also been found in yeast systems 
including Saccharmomyces cerevisiae. This includes GSTI and GSTII, whereby GSTII shares 
higher sequence and structural similarity to GST in Schistosoma japonicum and Rattus 
norvegicus. Despite this similarity, GST from yeast may be more compatible with expression 
in the yeast system, and should be further investigated in this system. 
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Figure 5.9 Structure of GST dimer from rat liver. The individual monomers within the GST dimer 
are shown in red and green; The N-terminus is shown in blue and the C-terminus in magenta. Residues 
present at the dimer interface shown in yellow.  Structure file obtained from RCSB PDB (6GSV,[137]).  
The possibility of steric hindrance, as mentioned above, is less prominent with the coiled-coil 
of CtIP and the leucine zipper of GCN4 due to the simplicity of the folds of these domains 
(Figure 5.10). The N- and C- termini are located on opposite ends of the domain when the 
dimer forms, and both the N and the C-termini are in close proximity because they form or are 
thought to form, parallel coiled-coils. This may be in part why little change occurred when 
CtIP or GCN4 were on the N- or C-terminus. GCN4 and CtIP were found to overall stabilise 
the disordered domain to a similar extent. Their similar dimerisation methods are likely to 
account for similar activities in this project. Both proteins were found to be more effective in 
the protection of Deaf1LID when fused to the activation domain, that is, when used as the prey 
protein.  
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Figure 5.10 Structure of GCN4 dimer from Saccharomyces cerevisiae. Each portion of GCN4 dimer 
shown in red and green. Residues in blue shows the N-termini, residues in magenta shows the C-termini. 
Structure file obtained from RCSB PDB (1CE9, [138]).  
Despite these results, when the same system was applied to RLIMBD/Ldb1 interactions no 
interaction was observed. There may be several reasons for this. Firstly, it is possible that the 
tethering of dimerisation domains, as above, does not work for all proteins. This was only 
shown to be effective with Deaf1LID, and previously with CtIPLID [134], both of which involve 
the binding of a disordered LID to Lmo4. RLIMBD may not be stabilised or protected, even if 
the dimerisation event is still taking place. Alternatively, this result could be a false negative 
artefact, resulting from the yeast two-hybrid system. For example, RLIM may not function 
properly in yeast, where it may not be able to fold and function properly, or it may be degraded, 
rendering it non-functional. Other reasons for incompatibility in this system include: (i) a lack 
of modifying enzymes in yeast (which are required for post translational modifications); (ii) 
interactions that are transient and may not be readily detected; (iii) or that the fused Gal4 
effector proteins may cause steric hindrance, obstructing the interaction [132, 133]. Difficulties 
such as these in yeast two-hybrid are widely documented and well known to occur. 
Troubleshooting these problems can be difficult due to low levels of protein expression in this 
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system. Rather than troubleshooting this method, future studies could investigate this 
interaction via other methodologies.  
It should also be noted that the original studies which suggested that RLIMBD was sufficient 
for binding was carried out in a mammalian expression system, using GST pull-down 
experiments. Similarly, experiments carried out in Chapter 4 where an interaction between full-
length RLIM and full-length Ldb1 was observed was also carried out in a mammalian 
expression system. A shortcoming of using a mammalian expression system for investigating 
mammalian protein interactions is the possibility that an intermediary protein binding to both 
RLIM and Ldb1, resulting in a false positive interaction [139]. If this is indeed occurring, the 
bridging protein may not be present in yeast, leading to a negative result in the yeast two-hybrid 
assays. It could be of use to further investigate this interaction in the mammalian system using 
purified proteins, rather than cell lysates, to minimise the potential of binding proteins being 
present.  
It would be of interest to further investigate this with a variety of proteins in different 
expression systems. As mentioned previously, disordered proteins or regions often degrade or 
aggregate during expression, making them difficult to study. The tethering of the dimerisation 
domains may be of use in these scenarios, and should be further studied in bacterial and 
mammalian systems. If disordered domains can successfully be expressed and purified using 
this method, attempts could also be made to cleave the dimerisation domains, to observe if the 
disordered domain remains stable.  
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Chapter 6. Final Remarks 
 
Overall the research described in this thesis aimed to further the understanding of binding 
within the pentameric complex, to investigate mammalian Ldb1 and Ldb1-like proteins from 
various organisms, to investigate the binding of RLIM and Ldb1, and to generate a potential 
method for the stabilisation of IDPs. 
The key findings in the context of the pentameric complex showed that USF1 may bind to the 
complex, to components other than Gata-1NF. This binding should be further investigated via 
the generation of mutations at the USF1 binding interface, as well as similar experiments using 
mammalian FOG1. Ldb1, one of the components of the pentameric complex, was investigated 
for its self-association properties, but was found to be largely insoluble following bacterial 
expression of the self-association domain. Ldb1-like proteins from other organisms, Adn1 and 
CeLdb1, were also found to be largely insoluble, only showing solubility in the presence of an 
MBP tag. It would be of interest to further investigate this self-association in other expression 
systems to attempt to improve solubility. A greater understanding of the mechanism of self-
association of Ldb1, and possibly Ldb1-like proteins could allow for further study in ways to 
up- or down-regulate self-association, and therefore the activation of β-globin genes. Some 
suggestions for experiments to do this are provided in Section 3.5.   
In addition to investigating the self-association of Ldb1, the interaction of Ldb1 and RLIM 
was investigated, in an attempt to further understand the regulation of Ldb1 protein levels. 
The binding of Ldb1 and RLIM could only be observed in a mammalian system, and 
truncation mutants could not be expressed. This was hypothesised to be due to RLIM’s 
intrinsic disorder, and to further investigate the Ldb1/RLIM minimal binding domains, RLIM 
would need to be stabilised. This led into the final aim: designing a potential method for the 
stabilisation of IDPs. This was initially successful in stabilising the binding of Deaf1LID to 
Lmo4, via the tethering of dimerisation domains from CtIP and GCN4. This method was then 
applied to RLIMBD, in binding to Ldb1, where no binding was observed. This method should 
still be investigated for use in other disordered proteins, as well as in various expression 
systems, as described in Section 4.6. The method could be of great use in further studies of 
disordered proteins. As IDPs are so common and have a wide variety of functions, a method 
 
Chapter 6. Final Remarks  101 
 
 
 
to effectively express these proteins to investigate properties such as structure and binding 
mechanisms could have substantial implications in a variety of areas.   
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Appendix A – Oligonucleotides  
 
The oligonucleotides used as primers for PCR are shown below. 
Construct Primer sequence 
CtIP (3C overlap site) 
Reverse 
AGAACCCGGACCCTGAAACAGCACTTCCAGAGAACC
AGAACCTGCTTGATGCTGTTGATCATT 
CtIP (TEV overlap site) 
Forward 
GGTACCGAAAACCTGTATTTCCAGGGAGGTAGTGGTA
GTCTAAAACAGGAACGAATCTTAGAT 
CtIP Forward GCGGATCCCTAAAACAGGAACGAATCTTAGAT 
CtIP pGAD10 Forward AACCCAAAAAAAGAGATCTCTCGAGGATCCATGCTA
AAACAGGAACGAATCTTAGAT 
CtIP pGAD10 Reverse CAGTATCTACGATTCATAGATCTGGAATTCTCACTAT
GCTTGATGCTGTTGATCATT 
CtIP Reverse GCGAATTCTCACTATGCTTGATGCTGTTGATCATT 
Deaf1LID (3C overlap 
site) Forward 
CTGGAAGTGCTGTTTCAGGGTCCGGGTTCTCCCGGGG
ACAGCTGCCAGATTGCCCC 
DEAF1LID (TEV 
overlap site) Reverse 
TCCCTGGAAATACAGGTTTTCGGTACCAGAACCGACA
GCTTTGGTGGGGGTGG 
Deaf1LID pGAD10 
Forward 
AACCCAAAAAAAGAGATCTCTCGAGGATCCATGGAC
AGCTGCCAGATTGCCCC 
Deaf1LID pGAD10 
Reverse 
CAGTATCTACGATTCATAGATCTGGAATTCTCACTAG
ACAGCTTTGGTGGGGGTGG 
GCN4 (3C overlap site) 
Reverse 
AGAACCCGGACCCTGAAACAGCACTTCCAGAGAACC
AGAACCACGTTCACCAACCAGTTTTT 
GCN4 (TEV overlap 
site) Forward 
GGTACCGAAAACCTGTATTTCCAGGGAGGTAGTGGTA
GTATGAAACAGCTGGAAGACAAAGT 
GCN4 Forward GCGGATCCATGAAACAGCTGGAAGACAAAGT 
GCN4 pGAD10 
Forward 
AACCCAAAAAAAGAGATCTCTCGAGGATCCATGAAA
CAGCTGGAAGACAAAGT 
GCN4 pGAD10 
Reverse 
CAGTATCTACGATTCATAGATCTGGAATTCTCACTAA
CGTTCACCAACCAGTTTTT 
GCN4 Reverse GCGAATTCTCACTAACGTTCACCAACCAGTTTTT 
GST (3C overlap site) 
Reverse 
AGAACCCGGACCCTGAAACAGCACTTCCAGAGAACC
AGAACCATCCGATTTTGGAGGATGGTC 
GST (TEV overlap site) 
Forward 
GGTACCGAAAACCTGTATTTCCAGGGAGGTAGTGGTA
GTATGTCCCCTATACTAGGTTATTGGAAAAT 
GST Forward GCGGATCCATGTCCCCTATACTAGGTTATTGGAAA 
GST pGAD10 Forward AACCCAAAAAAAGAGATCTCTCGAGGATCCATGTCCC
CTATACTAGGTTATTGGAAAAT 
GST pGAD10 Reverse CAGTATCTACGATTCATAGATCTGGAATTCTCACTAA
TCCGATTTTGGAGGATGGTC 
GST Reverse GCGAATTCTCACTAATCCGATTTTGGAGGATGGTC 
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Ldb1 pcDNA Forward  
GGATCCACTAGAACACATAATAGGATGCTGGATCGG
GATGTGGG 
Ldb1 pcDNA Reverse TGGATATCTGCAGAATTCTGATCATCACTGGGAAGCC
TGTGACGT 
Ldb1 pGBT9 Forward CAAAGACAGTTGACTGTATCGCCGGAATTTGGATCCA
TGCTGGATCGGGATGT 
Ldb1 pGBT9 Reverse AGAAATTCGCCCGGAATTAGCTTGGCTGCAGAATTCC
TATTATCACTGGGAAGCCTGTG 
Ldb1 residue 259 
Forward 
GGATCCACTAGAACACATAATAGGAAACGGAGGAAA
CGGAAGATG 
Ldb1 Reverse 
Transcriptase 
CGTCTTCTGCTCCCTG 
Ldb1LID (3C overlap 
site) Forward 
CTGGAAGTGCTGTTTCAGGGTCCGGGTTCTCCCGGGG
ATGTGATGGTGGTGGGGGAG 
Ldb1LID (TEV overlap 
site) Reverse 
TCCCTGGAAATACAGGTTTTCGGTACCAGAACCCTCG
TCGTCAATGCCGTTGG 
Ldb1LID pGAD10 
Forward 
AACCCAAAAAAAGAGATCTCTCGAGGATCCATGGAT
GTGATGGTGGTGGGGGAG 
Ldb1LID pGAD10 
Reverse 
CAGTATCTACGATTCATAGATCTGGAATTCTCACTACT
CGTCGTCAATGCCGTTGG 
Ldb2 pGAD10 Forward CCACCAAACCCAAAAAAAGAGATCTCTCGAGGATCC
ATGTCCAGCACACCACAT 
Ldb2 pGAD10 Reverse GTTTTTCAGTATCTACGATTCATAGATCTGGAATTCTC
ACTATTACTGGGAAGCCTGGG 
Ldb2 Reverse 
transcriptase 
TAGAGATTTGCGAATGGAA 
RLIM (3C overlap site) 
Forward 
CTGGAAGTGCTGTTTCAGGGTCCGGGTTCTCCCGGGA
TGGAGAACTCAGATTCTAA 
RLIM (TEV overlap 
site) 
Reverse 
TCCCTGGAAATACAGGTTTTCGGTACCAGAACCCACA
ACACTTTCTCTGTTC 
RLIM pcDNA Forward GGATCCACTAGAACACATAATAGGATGGAGAACTCA
GATTCTAACGATAA 
RLIM pcDNA Reverse TGGATATCTGCAGAATTCTGATCATCACACAACACTT
TCTCTGTTCC   
RLIM pGAD10 
Forward 
GTTTTTCAGTATCTACGATTCATAGATCTGGAATTCTC
ATTACTACACAACACTTTCTCTGTTC 
RLIM pGAD10 
Reverse 
CCACCAAACCCAAAAAAAGAGATCTCTCGAGGATCC
ATGGAGAACTCAGATTCTAA 
RLIM residue 306 
Forward 
GGATCCACTAGAACACATAATAGGGGCCAAAGACCT
CCAACCATA 
RLIM residue 306 
Reverse 
TGGATATCTGCAGAATTCTGATCATCAGCCAGATCCT
GAGGATTCACT 
RLIM residue 426 
Forward 
GGATCCACTAGAACACATAATAGGTCCAGCCGAAAT
GTGGAGAG 
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RLIM residue 426 
Reverse 
TGGATATCTGCAGAATTCTGATCATCAGGAGACTGAG
GCACTAGGC 
RLIMBD (3C site) 
Forward 
CTGGAAGTGCTGTTTCAGGGTCCGGGTTCTCCCGGGG
GCCAAAGACCTCCAACC 
RLIMBD (TEV overlap 
site) Reverse 
TCCCTGGAAATACAGGTTTTCGGTACCAGAACCGGAG
ACTGAGGCACTAGG 
RLIMBD pGAD10 
Forward 
AACCCAAAAAAAGAGATCTCTCGAGGATCCGGCCAA
AGACCTCCAACC 
RLIMBD pGAD10 
Reverse 
CAGTATCTACGATTCATAGATCTGGAATTCGGAGACT
GAGGCACTAGG 
 
Synthetic gene sequence shown below: 
Ldb2 
GGCAGCGGATCCATGTCCAGCACGCCGCACGACCCGTTTTACTCATCGCCGTTTG
GCCCGTTCTATCGCCGTCACACGCCGTATATGGTTCAGCCGGAATATCGCATCTA
CGAAATGAACAAACGCCTGCAAAGCCGTACCGAAGATAGCGATAATCTGTGGTG
GGATGCATTCGCGACCGAATTTTTCGAAGATGATGCGACGCTGACCCTGAGCTTT
TGCCTGGAAGACGGCCCGAAACGCTACACCATTGGTCGTACCCTGATTCCGCGTT
ATTTTAGCACCGTGTTCGAAGGTGGTGTGACCGATCTGTATTACATCCTGAAACA
TAGCAAAGAATCGTATCACAACAGCTCGATTACCGTGGATTGCGATCAGTGTGC
AATGGTGACCCAACATGGCAAACCGATGTTTACCAAAGTGTGTACCGAAGGTCG
CCTGATCCTGGAATTTACCTTCGACGATCTGATGCGTATTAAAACGTGGCATTTT
ACCATTCGTCAGTACCGCGAACTGGTGCCGCGCAGCATTCTGGCGATGCATGCAC
AAGATCCGCAGGTGCTGGATCAGCTGAGCAAAAACATCACCCGTATGGGTCTGA
CCAACTTTACCCTGAACTATCTGCGTCTGTGCGTGATTCTGGAACCGATGCAGGA
ACTGATGAGCCGCCATAAAACGTATAACCTGTCGCCGCGCGACTGCCTGAAAAC
GTGCCTGTTTCAGAAATGGCAACGTATGGTGGCACCGCCGGCGGAACCGACCCG
TCAGCCGACGACCAAACGCCGTAAACGTAAAAACAGCACCTCATCCACGAGCAA
TAGCTCCGGCGGTAACACGACCAACTCTTCAGGTAGCAAAAAGAAAACCCCGGC
GGCCAGCCTGTCGCTGGCGACCCAAGTGCCGGATGTGATGGTGGTTGGTGAACC
GACCCTGATGGGCGGTGAATTTGGCGATGAAGACGAACGTCTGATTACCCGTCT
GGAAAACACGCAGTATGATGCGGCTAATGGTATGGATGACGAAGAAGACTTTAA
TAACTCTCCGGCGCTGGGCAATAACAGCCCGTGGAACAGCAAACCGCCGGCAAC
CCAGGAAACCAAATCAGAAAACGCCCCGCCGCAGGCATCTCAATGATAGTAAGA
ATTCGCATGC 
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Appendix B – Protein Sequences used for Chapter 3 
 
Gata-1NF 
EARECVNCGATATPLWRRDRTGHYLCNACGLYHKMNGQNRPLIRPKKRM   
Lmo1-Ldb1LID 
GSGKQKGCAGCNRKIKDRYLLKALDKYWHEDCLKCACCDCRLGEVGSTLYTKANL
ILCRRDYLRLFGTTGNCAACSKLIPAFEMVMRARDNVYHLDCFACQLCNQRFCVGD
KFFLKNNMILCQVDYEEGHLNGTGGSGGSGGSGGSSQVPDVMVVGEPTLMGGEFG
DEDERLITRLENTQFDAANGIDDE 
GFP-USF1 
MSYYHHHHHHDYDIPTTENLYFLGAMEYKLILNGKTLKGETTTEAVDAATAEKVFK
QYANDNGVDGEWTYDDATKTFTVTEIPTTENLYFQGELGSASKGEELFTGVVPILVE
LDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFSYGVQCFAR
YPDHMKQHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDF
KEDGNILGHKLEYNYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNT
PIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITHGMDELYKGGTG
GSGGSGGLLKPARFMCLPCGIAFSSPSTLEAHQA YYCSHRI 
 
Tal1 
MGSSHHHHHHSQDPVVRRIFTNSRERWRQQNVNGAFAELRKLIPTHPPDKKLSKNEI
LRLAMKYINFLAKLLNDQ      
E47 
MADLRRMANNARERVRVRDINEAFRELGRMCQLHLKSDKAQTKLLILQQAVQVIL
GLEQQVRER 
Gata-1NC 
EARECVNCGATATPLWRRDRTGHYLCNACGLYHKMNGQNRPLIRPKKRMIVSKRA
GTQCTNCQTTTTTLWRRNASGDPVCNACGLYFKLHQVNRPLTMRKDGIQTRNRKA
SGKGKKKRG 
Ldb1LID-Lmo1LIM2 
MADLSSQVPDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEGGSGGSG
GSGKQKGCAGCNRKIKDRYLLKALDKYWHEDCLKCACCDCRLGEVGSTLYTKANL
ILCRRDYLRLFGTTGNCAACSKLIPAFEMVMRARDNVYHLDCFACQLCNQRFCVGD
KFFLKNNMILCQVDYEEGHLNGT 
Ldb1 
MLDRDVGPTPMYPPTYLEPGIGRHTPYGNQTDYRIFELNKRLQNWTEECDNLWWD
AFTTEFFEDDAMLTITFCLEDGPKRYTIGRTLIPRYFRSIFEGGATELYYVLKHPKEAF
HSNFVSLDCDQGSMVTQHGKPMFTQVCVEGRLYLEFMFDDMMRIKTWHFSIRQHR
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ELIPRSILAMHAQDPQMLDQLSKNITRCGLSNSTLNYLRLCVILEPMQELMSRHKTYS
LSPRDCLKTCLFQKWQRMVAPPAEPARQQPSKRRKRKMSGGSTMSSGGGNTNNSN
SKKKSPASTFALSSQVPDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDE
DSFNNSPALGANSPWNSKPPSSQESKSENPTSQASQ 
 
CeLdb1_L 
CVVIFLKFLFSDNGNNQHGTEAAFGRLAQSYRIQDLLFIIVIFFRAIHIMMFHRPPSARP
PLNHVDQLKSLQATALGKPGMRSQATEPQPIGNTVSPLEFRIHDMNRRLYIFSSTGVS
ENDQQQWWDAFSHEFFDDDCKLWFVIGSEPVAFASRERYIINRQFIPKFFRSIFDSGM
RELQYVLRGPSRECTLANGSQAYENENVLQITRYDQSSQFEVNTEGKLYVEFAPFDE
VMNYRIKAWTLELKRSNEFVYNQNTADYRVEAQNPEQENKPRMGFFKSTFNLMTM
LKILDPMQSIMSSAKSAPAITPREVMKRTLFQHHQVRQQNMRQQQLNQQMMIPAPE
PEKPKPARKRQRKPAANPRGSKKA 
CeLdb1_S 
ALGKPGMRSQATEPQPIGNTVSPLEFRIHDMNRRLYIFSSTGVSENDQQQWWDAFSH
EFFDDDCKLWFVIGSEPVAFASRERYIINRQFIPKFFRSIFDSGMRELQYVLRGPSREC
TLANGSQAYENENVLQITRYDQSSQFEVNTEGKLYVEFAPFDEVMNYRIKAWTLEL
KRSNEFVYNQNTADYRVEAQNPEQENKPRMGFFKS 
Adn1_L 
VANYASMMYHNGSNILGYGVLRLLQYNEQLMSGWESTMKDDIGYWRRFVHDFYT
EKGTFRYNIDYKDSPNQEPKLFELSYAALPRFLYLSYCGKLKKMSFLLGNTKEFAIPN
NGYFVESSRASILYQYQGGVQVIVSGHLRAHFFRAPLLKLDSLEFSAVGHSEYLLREL
MTNASLALSQSRPPQNQIQHDGVKSEDPSSESVNINSSSSLLPDSPVNEYGLEPHIMRF
MEITETISGMRDLIAFTLAQRSGPTSALHKFATALQQQHQMQKSTSS 
Adn1_S 
VANYASMMYHNGSNILGYGVLRLLQYNEQLMSGWESTMKDDIGYWRRFVHDFYT
EKGTFRYNIDYKDSPNQEPKLFELSYAALPRFLYLSYCGKLKKMSFLLGNTKEFAIPN
NGYFVESSRASILYQYQGGVQVIVSGHLRAHFFRAPLLKLDSLEFSAVGHSEYLLREL
MTNASLALSQSRPPQNQIQHDGVKSEDPSSES 
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Appendix C – Protein Sequences used for Chapter 4 
 
RLIM 
MENSDSNDKGSDQSAAQRRSQMDRLDREEAFYQFVNNLSEEDYRLMRDNNLL 
GTPGESTEEELLRRLQQIKEGPPPQSPDENRAGESSDDVTNSDSIIDWLNSVRQT 
GNTTRSGQRGNQSWRAVSRTNPNSGDFRFSLEINVNRNNGSQTSENESEPSTRR 
LSVENMESSSQRQMENSASESASARPSRAERNSTEAVTEVPTTRAQRRARSRSP 
EHRRTRARAERSVSPLQPTSEIPRRAPTLEQSSENEPEGSSRTRHHVTLRQQISGP 
ELLGRGLFAASGSRNPSQGTSSSDTGSNSESSGSGQRPPTIVLDLQVRRVRPGEY 
RQRDSIASRTRSRSQAPNNTVTYESERGGFRRTFSRSERAGVRTYVSTIRIPIRRIL 
NTGLSETTSVAIQTMLRQIMYGFGELSYFMYSDSDSEPSASVSSRNVERVESRN 
GRGSSGGGNSSGSSSSSSPSPSSSGESSESSSKMFEGSSEGGSSGPSRRDGRHRAP 
VTFDESGSLPFLSLAQFFLLNEDDEDQPRGLTKEQIDNLAMRSFGENDALKTCS 
VCITEYTEGNKLRKLPCSHEFHVHCIDRWLSEN STCPICRRAVLSSGNRESVV 
 
RLIMBD 
GQRPPTIVLDLQVRRVRPGEYRQRDSIASRTRSRSQAPNNTVTYESERGGFRRTFSRS
ERAGVRTYVSTIRIPIRRILNTGLSETTSVAIQTMLRQIMTGFGELSYFMYSDSDSEPSA
SVS 
RLIMRING 
SSRNVERVESRNGRGSSGGGNSSGSSSSSSPSPSSSGESSESSSEMFEGSSEGGSSGPSR
RDGRHRAPVTFDESGSLPFLSLAQFFLLNEDDEDQPRGLTKEQIDNLAMRSFGENDA
LKTCSVCITEYTEGNKLRKLPCSHEYHVHCIDRWLSENSTCPI CRRAVLSSGNRESVV 
Ldb1 
MLDRDVGPTPMYPPTYLEPGIGRHTPYGNQTDYRIFELNKRLQNWTEECDNLWWD
AFTTEFFEDDAMLTITFCLEDGPKRYTIGRTLIPRYFRSIFEGGATELYYVLKHPKEAF
HSNFVSLDCDQGSMVTQHGKPMFTQVCVEGRLYLEFMFDDMMRIKTWHFSIRQHR
ELIPRSILAMHAQDPQMLDQLSKNITRCGLSNSTLNYLRLCVILEPMQELMSRHKTYS
LSPRDCLKTCLFQKWQRMVAPPAEPARQQPSKRRKRKMSGGSTMSSGGGNTNNSN
SKKKSPASTFALSSQVPDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDE
DSFNNSPALGANSPWNSKPPSSQESKSENPTSQASQ 
 
Ldb1SA/LCCD 
MLDRDVGPTPMYPPTYLEPGIGRHTPYGNQTDYRIFELNKRLQNWTEECDNLWWD
AFTTEFFEDDAMLTITFCLEDGPKRYTIGRTLIPRYFRSIFEGGATELYYVLKHPKEAF
HSNFVSLDCDQGSMVTQHGKPMFTQVCVEGRLYLEFMFDDMMRIKTWHFSIRQHR
ELIPRSILAMHAQDPQMLDQLSKNITRCGLSNSTLNYLRLCVILEPMQELMSRHKTYS
LSPRDCLKTCLFQKWQRMVAPPAEPARQQPSK 
Ldb1LID 
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KRRKRKMSGGSTMSSGGGNTNNSNSKKKSPASTFALSSQVPDVMVVGEPTLMGGEF
GEDERLITRLENTQFDAANGIDDEDSFNNSPALGANSPWNSKPPSSQESKSENPTSQA
SQ 
Ldb2 
MSSTPHDPFYSSPFGPFYRRHTPYMVQPEYRIYEMNKRLQSRTEDSDNLWWDAFAT
EFFEDDATLTLSFCLEDGPKRYTIGRTLIPRYFSTVFEGGVTDLYYILKHSKESYHNSSI
TVDCDQCAMVTQHGKPMFTKVCTEGRLILEFTFDDLMRIKTWHFTIRQYRELVPRSI
LAMHAQDPQVLDQLSKNITRMGLTNFTLNYLRLCVILEPMQELMSRHKTYNLSPRD
CLKTCLFQKWQRMVAPPAEPTRQPTTKRRKRKNSTSSTSNSSGGNTTNSSGSKKKTP
AASLSLATQVPDVMVVGEPTLMGGEFGDEDERLITRLENTQYDAANGMDDEEDFN
NSPALGNNSPWNSKPPATQETKSENAPPQASQ 
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Appendix D – Protein Sequences used for Chapter 5 
 
Ldb1LID 
GSMDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEDSFNNSPALGANS
PWNSKPPSSQESKSENPTSQASQ 
 
Deaf1LID 
MDSCQIAPFPEAALPTSHPKIVLTSLPALAVPPSTPTKAV 
 
GST 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPY
YIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCL
DAFPKLVCFKKRIEAIPQIDKYLESSKYIAWPLQGWQATFGGGDHPPKSD 
 
GCN4 leucine zipper 
MKQLEDKVEELLSKNYHLENEVARLKKLVGER 
 
CtIP coiled-coil 
LKQERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTEEHMR
KKQQEFENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQA 
 
GST-Ldb1LID 
GSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSK
DFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGSGSLE
VLFQGPGSPG DVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDE 
 
GCN4-Ldb1LID 
GSMKQLEDKVEELLSKNYHLENEVARLKKLVGERGSGSLEVLFQGPGSPGDVMVV
GEPTLMGGEFGDEDERLITRLENTQFDAANGIDDE 
 
CtIP-Ldb1LID 
GSMLKQERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTEEH
MRKKQQEFENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQAGSGSL
EVLFQGPGSPGDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDE 
 
Ldb1LID-GST 
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DVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEGTENLYFQGGSGSMSPI
LGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDG
DVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLK
VDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFP
KLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSD 
 
Ldb1LID-GCN4 
DVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEGTENLYFQGGSGSMKQ
LEDKVEELLSKNYHLENEVARLKKLVGER 
 
Ldb1LID-CtIP 
DVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEGTENLYFQGGSGSLKQ
ERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTEEHMRKKQ
QEFENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQA 
 
GST-Ldb1LID-GCN4 
GSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSK
DFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGSLEV
LFQGPGSPGDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEGTENLYFQ
GGSGSMKQLEDKVEELLSKNYHLENEVARLKKLVGER 
 
GST-Ldb1LID-CtIP 
GSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSK
DFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGSLEV
LFQGPGSPGDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEGTENLYFQ
GGSGSLKQERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTE
EHMRKKQQEFENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQA 
 
GCN4-Ldb1LID-GST 
GSMKQLEDKVEELLSKNYHLENEVARLKKLVGERGSGSLEVLFQGPGSPGDVMVV
GEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEGTENLYFQGGSGSMSPILGYWK
IKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLT
QSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLS
KLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCF
KKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSD 
 
GCN4-Ldb1LID-CtIP 
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GSMKQLEDKVEELLSKNYHLENEVARLKKLVGERGSGSLEVLFQGPGSPGDVMVV
GEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEGTENLYFQGGSGSLKQERILDA
QRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTEEHMRKKQQEFENIR
QQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQA 
 
CtIP-Ldb1LID-GST 
GSMKGSMLKQERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCA
VTEEHMRKKQQEFENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQ
AGSLEVLFQGPGSPGDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEGT
ENLYFQGGSGSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKK
FELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIR
YGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDAL
DVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDH
PPKSD 
 
CtIP-Ldb1LID-GCN4 
GSMKGSMLKQERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCA
VTEEHMRKKQQEFENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQ
AGSLEVLFQGPGSPGDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDEGT
ENLYFQGGSGSMKQLEDKVEELLSKNYHLENEVARLKKLVGER 
 
GST-Deaf1LID 
GSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSK
DFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLESSKYIAWPLQGWQATFGGGDHPPKSDGSGSLE
VLFQGPGSPGDSCQIAPFPEAALPTSHPKIVLTSLPALAVPPSTPTKAV 
 
GCN4-Deaf1LID 
GSMKQLEDKVEELLSKNYHLENEVARLKKLVGERGSGSLEVLFQGPGSPGDSCQIAP
FPEAALPTSHPKIVLTSLPALAVPPSTPTKAV 
 
CtIP-Deaf1LID 
GSMLKQERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTEEH
MRKKQQEFENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQAGSGSL
EVLFQGPGSPGDSCQIAPFPEAALPTSHPKIVLTSLPALAVPPSTPTKAV—EF 
 
Deaf1LID-GST 
DSCQIAPFPEAALPTSHPKIVLTSLPALAVPPSTPTKAVGSGTENLYFQGGSGSMSPIL
GYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDG
DVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLK
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VDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFP
KLVCFKKRIEAIPQIDKYLESSKYIAWPLQGWQATFGGGDHPPKSD 
 
Deaf1LID-GCN4 
DSCQIAPFPEAALPTSHPKIVLTSLPALAVPPSTPTKAVGSGTENLYFQGGSGSMKQLE
DKVEELLSKNYHLENEVARLKKLVGER 
 
Deaf1LID-CtIP 
DSCQIAPFPEAALPTSHPKIVLTSLPALAVPPSTPTKAVGSGTENLYFQGGSGSLKQER
ILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTEEHMRKKQQE
FENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQA 
 
GST-Deaf1LID-GCN4 
GSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSK
DFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGSLEV
LFQGPGSPGDSCQIAPFPEAALPTSHPKIVLTSLPALAVPPSTPTKAVGTGSENLYFQG
GSGSMKQLEDKVEELLSKNYHLENEVARLKKLVGER 
 
GST-Deaf1LID-CtIP 
GSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSK
DFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGSLEV
LFQGPGSPGDSCQIAPFPEAALPTSHPKIVLTSLPALAVPPSTPTKAVGSGTENLYFQG
GSGSMKGSMLKQERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDR
CAVTEEHMRKKQQEFENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQ
HQA 
 
GCN4-Deaf1LID-GST 
GSMKQLEDKVEELLSKNYHLENEVARLKKLVGERGSGSLEVLFQGPGSPGDSCQIAP
FPEAALPTSHPKIVLTSLPALAVPPSTPTKAVGSGTENLYFQGGSGSMSPILGYWKIKG
LVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQS
MAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKL
PEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFK
KRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSD 
 
GCN4-Deaf1LID-CtIP 
GSMKQLEDKVEELLSKNYHLENEVARLKKLVGERGSGSLEVLFQGPGSPGDSCQIAP
FPEAALPTSHPKIVLTSLPALAVPPSTPTKAVGSGTENLYFQGGSGSLKQERILDAQRL
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EEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTEEHMRKKQQEFENIRQQ
NLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQA 
 
CtIP-Deaf1LID-GST 
GSMLKQERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTEEH
MRKKQQEFENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQAGSLE
VLFQGPGSPGDSCQIAPFPEAALPTSHPKIVLTSLPALAVPPSTPTKAVGSGTENLYFQ
GGSGSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEF
PNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIA
YSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYM
DPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSD 
 
CtIP-Deaf1LID-GCN4 
GSMLKQERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTEEH
MRKKQQEFENIRQQNLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQAGSGSL
EVLFQGPGSPGDSCQIAPFPEAALPTSHPKIVLTSLPALAVPPSTPTKAVGSGTENLYF
QGGSGSMKQLEDKVEELLSKNYHLENEVARLKKLVGER 
 
 
